var title_f6_10_6304="SCFE epiphyseal shaft angle";
var content_f6_10_6304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Epiphyseal-shaft angle of Southwick",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One line is drawn between the anterior and posterior tips of the epiphysis at the level of the growth plate. A second line is drawn perpendicular to the first. A third line is drawn along the mid-axis of the femoral shaft. The epiphyseal-shaft angle is measured at the intersection of the second and third lines. It is measured for both hips. The magnitude of slip displacement is the angle of the involved hip minus the angle of the contralateral normal hip (or minus 12 degrees if the slip is bilateral).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6304=[""].join("\n");
var outline_f6_10_6304=null;
var title_f6_10_6305="Scabies vulva";
var content_f6_10_6305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6305=[""].join("\n");
var outline_f6_10_6305=null;
var title_f6_10_6306="Solar lentigo hand 2";
var content_f6_10_6306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solar lentigines presenting as brown macules on the dorsum of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple brown macules are present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6306=[""].join("\n");
var outline_f6_10_6306=null;
var title_f6_10_6307="Variations in the cystic and hepatic ducts";
var content_f6_10_6307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Variations in the cystic and hepatic ducts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Variations in the cystic and hepatic ducts are depicted here:",
"    <br>",
"     (A) Low union.",
"     <br>",
"      (B) High union.",
"      <br>",
"       (C) Swerving course.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6307=[""].join("\n");
var outline_f6_10_6307=null;
var title_f6_10_6308="Famciclovir: An overview";
var content_f6_10_6308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Famciclovir: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6308/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6308/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6308/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6308/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6308/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6308/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/10/6308/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    is an oral prodrug which is converted by first-pass metabolism to the antiviral drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     Penciclovir",
"    </a>",
"    , upon intracellular uptake, is monophosphorylated by virally-encoded thymidine kinase and, subsequently, converted to a triphosphate by cellular enzymes. Penciclovir triphosphate preferentially inhibits the DNA polymerase of susceptible viruses; at clinically relevant levels, there is no substantial effect upon cellular DNA polymerase, thereby minimizing side effects to the host [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This mechanism is similar to that described for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ; however, compared to acyclovir triphosphate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    triphosphate has a lower affinity for viral DNA polymerase but a longer intracellular half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spectrum of activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     Penciclovir",
"    </a>",
"    is active against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). Epstein-Barr virus is also susceptible in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    are similar to those described for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/3\">",
"     3",
"    </a>",
"    ]. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced or absent thymidine kinase",
"     </li>",
"     <li>",
"      Altered thymidine kinase activity resulting in decreased",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      phosphorylation",
"     </li>",
"     <li>",
"      Altered viral DNA polymerase with decreased affinity for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      triphosphate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H4#H4\">",
"     \"Acyclovir: An overview\", section on 'Mechanism of resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant strains of HSV and VZV exhibit cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    ; reduced or absent viral thymidine kinase is the primary mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. However, some acyclovir-resistant and foscarnet-resistant isolates remain susceptible to penciclovir. These strains demonstrate altered thymidine kinase and DNA polymerase substrate specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BASIC PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    is well absorbed, featuring an oral bioavailability of 77 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/7\">",
"     7",
"    </a>",
"    ]. Prompt first-pass metabolism in the intestine and liver results in conversion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    . A 500 mg dose of famciclovir yields peak penciclovir levels of 2.7 to 4.0",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    with a plasma half-life of 2.1 to 2.7 hours. Food has no clinically important effect upon these levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A key feature of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in HSV-infected cells, and 7 to 14 hours in VZV-infected cells. In comparison, the intracellular half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    triphosphate is one hour or less [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    requires less frequent dosing.",
"   </p>",
"   <p>",
"    Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     Penciclovir",
"    </a>",
"    is removed by hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/1\">",
"     1",
"    </a>",
"    ]. Well-compensated chronic liver disease does not require dose modification, but pharmacokinetic studies in patients with poorly compensated hepatic insufficiency have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    is very well tolerated, with a side effect profile similar to those of placebo and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , although long-term safety data are unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .) A review of over 1600 patients receiving famciclovir for herpes zoster or genital herpes revealed an adverse event profile not significantly different from placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    has been assigned to Pregnancy Category B; animal studies suggest safety, although there have been no adequate studies in pregnant women. In some cases, the potential benefits of therapy may outweigh the potential risks to the fetus. In order to monitor the outcomes of pregnancies exposed to this drug, SmithKline Beecham maintains a Famvir Pregnancy Registry at 800-366-8900, ext. 5231 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     USE OF FAMCICLOVIR IN IMMUNOCOMPETENT PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    is one possible treatment option for patients with acute herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and those with primary and recurrent genital herpes infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The management and treatment of these infections is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     USE OF FAMCICLOVIR IN IMMUNOCOMPROMISED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    is one potential treatment option for herpes zoster and primary and recurrent genital herpes in immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6308/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The approach to the treatment of genital herpes infections in the HIV-infected host is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34024?source=see_link\">",
"     \"Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414793\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      is an oral prodrug which is converted by first-pass metabolism to the antiviral drug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"       penciclovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon intracellular uptake,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"       penciclovir",
"      </a>",
"      is mono-phosphorylated by virally-encoded thymidine kinase and subsequently converted to a triphosphate by cellular enzymes. Penciclovir triphosphate preferentially inhibits the DNA polymerase of susceptible viruses. At clinically relevant levels, there is no substantial effect upon cellular DNA polymerase, thereby minimizing side effects to the host. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"       Penciclovir",
"      </a>",
"      is active against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms of resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"       penciclovir",
"      </a>",
"      are similar to those described for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      . Most acyclovir-resistant strains of HSV and VZV exhibit cross-resistance to penciclovir. Resistance is rarely seen among immunocompetent hosts but has been well-documented in immunocompromised hosts, such as transplant recipients and HIV-infected patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A key feature of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"       penciclovir",
"      </a>",
"      is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in HSV-infected cells, and 7 to 14 hours in VZV-infected cells. In comparison, the intracellular half-life of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      triphosphate is one hour or less. As a result,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      requires less frequent dosing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      is very well tolerated, with a side effect profile similar to that of placebo, although long-term safety data are unavailable. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Famvir (famciclovir) prescribing information. SmithKline Beecham, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/2\">",
"      Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/3\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/4\">",
"      Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/5\">",
"      Boyd MR, Safrin S, Kern ER. Penciclovir: A review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 1993; 4(Suppl 1):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/6\">",
"      Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993; 37:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/7\">",
"      Vere Hodge RA. Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/8\">",
"      Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994; 38:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/9\">",
"      Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/10\">",
"      Boon RJ, Griffin DR. Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Neurology 1995; 45:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/11\">",
"      Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first-episode genital herpes. IDCP 1997; 6:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/12\">",
"      Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996; 276:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/13\">",
"      Sacks SL. Management of recurrent genital herpes &mdash; episodic therapy with famciclovir. IDCP 1997; 6:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/14\">",
"      Frechette, G, Romanowski, B. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. Can J Infect Dis 1997; 8:44A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6308/abstract/15\">",
"      Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8338 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6308=[""].join("\n");
var outline_f6_10_6308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1414793\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spectrum of activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BASIC PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      USE OF FAMCICLOVIR IN IMMUNOCOMPETENT PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      USE OF FAMCICLOVIR IN IMMUNOCOMPROMISED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1414793\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34024?source=related_link\">",
"      Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_10_6309="Chronic lymphocytic leukemia (CLL) in adults";
var content_f6_10_6309=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/10/6309/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6309/contributors\" id=\"au3063\">",
"       Kanti R Rai, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6309/contributors\" id=\"au5152\">",
"       Michael J Keating, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/10/6309/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6309/contributors\" id=\"se3198\">",
"       Richard A Larson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/10/6309/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6309/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/10/6309?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CHRONIC LYMPHOCYTIC LEUKEMIA OVERVEIW",
"     </span>",
"    </p>",
"    <p>",
"     Chronic lymphocytic leukemia, often referred to as CLL, is a type of cancer of the blood. It is one of a group of diseases that affects a type of white blood cell called a lymphocyte. The lymphocytes help the body fight infection.",
"    </p>",
"    <p>",
"     CLL and small lymphocytic lymphoma are variants of the same disease. If you have been diagnosed with small lymphocytic lymphoma, abbreviated as \"SLL,\" the information in this article applies to you, too.",
"    </p>",
"    <p>",
"     In chronic lymphocytic leukemia, abnormally high numbers of ineffective lymphocytes are found in the blood",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     bone marrow (the spongy area in the middle of large bones where blood cells are formed). In SLL, these same cells are commonly found in the lymph nodes. The abnormal cells cannot fight infection as normal lymphocytes do, but instead collect in lymph nodes and other areas, such as the liver and spleen. The accumulation of ineffective lymphocytes can interfere with the production of other blood cells, such as red cells and platelets.",
"    </p>",
"    <p>",
"     Unlike other types of leukemia, CLL usually progresses slowly. In many cases, it causes the patient little, if any, problems in its early stages. Patients may live with chronic lymphocytic leukemia for decades. Some patients, however, live for a shorter period. Many times, it is diagnosed, only incidentally, by blood tests that are performed during a routine physical exam. In other cases, symptoms cause the person to seek medical care.",
"    </p>",
"    <p>",
"     Careful analysis of the patient's blood and physical condition help to determine the stage of the disease &mdash; a crucial first step in deciding on the proper course of treatment. Unlike patients with many other types of cancer, some patients with CLL do not benefit from early, aggressive treatment, but rather, do better with careful long-term monitoring of the disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      STAGING OF CHRONIC LYMPHOCYTIC LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     The natural history of CLL may vary considerably from one person to another. Some people become sick within a short time of diagnosis; others live comfortably for years without problems. Determining which patients are most likely to get sick, and therefore most likely to benefit from treatment, is an important task. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link\">",
"      \"Staging and prognosis of chronic lymphocytic leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Two systems for staging CLL are now in use. Both systems are based upon results of the physical examination and blood tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      The Rai system",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Rai system is based on an analysis of how the body is affected by the abnormal lymphocytes [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/1\">",
"      1",
"     </a>",
"     ]. There are five stages. The higher numbers indicate a more advanced stage of disease:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stage 0: Increased numbers of abnormal lymphocytes are found in the blood or bone marrow; lymph",
"       <span class=\"nowrap\">",
"        nodes/organs",
"       </span>",
"       are not swollen; and production of red cells and platelets is normal",
"      </li>",
"      <li>",
"       Stage I: Increased abnormal lymphocytes and enlarged lymph nodes",
"      </li>",
"      <li>",
"       Stage II: Increased abnormal lymphocytes with enlarged liver or spleen, with or without enlarged lymph nodes",
"      </li>",
"      <li>",
"       Stage III: Increased abnormal lymphocytes with anemia (low red blood cell count), with or without an enlarged spleen, liver, or lymph nodes",
"      </li>",
"      <li>",
"       Stage IV: Increased abnormal lymphocytes with a low platelet count, with or without anemia, enlarged liver, spleen, or lymph nodes",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      The Binet system",
"     </span>",
"     &nbsp;&mdash;&nbsp;This system considers the five possible sites where lymphocytes can collect (lymph nodes in the neck, armpit, and groin, and lymphocyte-containing channels in the spleen and liver (",
"     <a class=\"graphic graphic_figure graphicRef64350 \" href=\"UTD.htm?23/55/24439\">",
"      figure 1",
"     </a>",
"     )), and also whether anemia or low platelet counts are present [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/2\">",
"      2",
"     </a>",
"     ]. There are three stages:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Stage A: Fewer than three involved sites",
"      </li>",
"      <li>",
"       Stage B: Three or more involved sites",
"      </li>",
"      <li>",
"       Stage C: Presence of anemia or low platelet counts",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      What the CLL stages mean",
"     </span>",
"     &nbsp;&mdash;&nbsp;Staging CLL helps determine how likely it is that you will develop serious problems related to your illness. Patients at Rai stage 0 are considered at low risk, those at stages I or II are at intermediate risk, and those at stage III or IV are at high risk. Similarly, patients characterized according to the Binet system have progressively increasing risk, with Stage A as the lowest and Stage C as the highest risk group.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      When is treatment needed?",
"     </span>",
"     &nbsp;&mdash;&nbsp;As noted above, treatment is not always required for chronic lymphocytic leukemia. Some studies have shown that patients without symptoms of CLL (also called \"smoldering\" disease) are no more likely to die than a similar",
"     <span class=\"nowrap\">",
"      age/sex",
"     </span>",
"     person who does not have chronic lymphocytic leukemia. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Management of asymptomatic chronic lymphocytic leukemia'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     However, there are certain groups of patients in whom treatment is generally indicated. This includes patients with:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Symptoms of anemia",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       low platelets (Rai stages III or IV, or Binet stage C)",
"      </li>",
"      <li>",
"       Disease-related symptoms such as weakness, night sweats, weight loss, painful lymph node swelling, or fever",
"      </li>",
"      <li>",
"       Autoimmune hemolytic anemia",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       low platelets (when the immune system destroys red blood cells or platelets) that does not respond to treatment with glucocorticoids, such as prednisone.",
"      </li>",
"      <li>",
"       Progressive disease, as demonstrated by rapidly increasing white cells in the blood,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       rapidly enlarging lymph nodes, spleen, or liver",
"      </li>",
"      <li>",
"       Repeated infections",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      MANAGEMENT OF ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     Although people who do not have symptoms of chronic lymphocytic leukemia are not usually treated for their disease, they should be monitored regularly with blood tests and a physical examination. This is usually performed every three months for at least the first year after diagnosis. Depending upon the results of these tests, it may be possible to estimate how aggressive your disease will be in the future.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TREATMENT OF LOCALIZED CHRONIC LYMPHOCYTIC LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     People who have stage I chronic lymphocytic leukemia (which causes increased abnormal lymphocytes and enlarged lymph nodes) are sometimes treated with radiation therapy. Radiation therapy (RT) refers to the exposure of tissues to high-energy x-rays in order to slow or stop their growth. Exposure to x-rays damages cells. Unlike normal cells, leukemic cells cannot repair the damage caused by exposure to x-rays, particularly when it is administered over several days. This prevents the leukemic cells from growing further and causes them to eventually die. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"      \"Overview of the treatment of chronic lymphocytic leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      TREATMENT OF ADVANCED OR SYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with advanced or symptomatic chronic lymphocytic leukemia are generally treated first with chemotherapy. Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (like cancer cells) to divide or multiply. Because most of an adult's normal cells are not actively dividing or multiplying, they are not affected by chemotherapy. However, the bone marrow (where the blood cells are produced), the hair follicles, and the lining of the gastrointestinal (GI) tract are all growing. The side effects of chemotherapy drugs are related to effects on these and other normal tissues.",
"    </p>",
"    <p>",
"     A chemotherapy drug or combination of drugs is referred to as a regimen. Regimens used for the treatment of follicular lymphoma may include a single agent taken by mouth on a daily basis, while other regimens are given intravenously in treatment cycles.",
"    </p>",
"    <p>",
"     A cycle of chemotherapy refers to the time it takes to give the drugs and the time required for the body to recover. For example, a typical chemotherapy regimen is at least a one-hour IV infusion of two or more different chemotherapy medications given once every three to four weeks. This three- or four-week period is one cycle of therapy. If this regimen were repeated for a total of three or four cycles, it would take up to four months to complete.",
"    </p>",
"    <p>",
"     People with advanced or symptomatic chronic lymphocytic leukemia are usually treated with a chemotherapy regimen that contains one or more of these agents:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Fludarabine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fludarabine is a chemotherapy drug that, when used in combination regimens, can often induce partial or complete remission of chronic lymphocytic leukemia. The most common side effects are low blood counts and fever. Older patients seem to be at higher risk of serious side effects from this medicine, including an increased risk of severe infections. (See",
"     <a class=\"local\" href=\"#H27\">",
"      'Infection'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Rituximab",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rituximab is a monoclonal antibody that treats chronic lymphocytic leukemia by attacking specific substances (antigens) on the surface of the leukemic cells. This type of treatment has advantages over other cancer treatments such as chemotherapy, which targets all rapidly growing cells.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Cyclophosphamide (Cytoxan)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cyclophosphamide is a chemotherapy drug that may be used in combination with other drugs in people with chronic lymphocytic leukemia. It can be given by mouth or through an intravenous (IV) line. Side effects include low blood counts, nausea and vomiting, hair loss, and irritation of the bladder.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Alemtuzumab",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alemtuzumab is a monoclonal antibody that can be used to treat CLL by attacking specific substances (antigens) on the surface of leukemic cells. The antigens targeted by alemtuzumab are different from those targeted by rituximab.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Bendamustine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bendamustine may be given by itself or in combination with rituximab as an initial treatment of advanced or symptomatic CLL, as well as in previously treated CLL patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Chlorambucil",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chlorambucil was the primary agent used to treat CLL for decades prior to studies that demonstrated greater tumor shrinkage yet similar survival rates with fludarabine treatment. Chlorambucil may still be an appropriate initial treatment for some patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      First line treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is no agreed upon standard treatment regimen for symptomatic chronic lymphocytic leukemia. Experts in the field use different treatment approaches. Because experts are not sure which regimen is most effective, all patients with advanced or symptomatic chronic lymphocytic leukemia are advised to enroll in a clinical trial, if possible. (See",
"     <a class=\"local\" href=\"#H31\">",
"      'Clinical trials'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     The combination of fludarabine and rituximab, sometimes with cyclophosphamide, is often used as a first-line treatment of advanced or symptomatic chronic lymphocytic leukemia [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/3\">",
"      3",
"     </a>",
"     ]. Overall survival rates appear to be the same with these two regimens, but response rates are higher with the combination of fludarabine, cyclophosphamide, rituximab (FCR) while toxicity is lower with fludarabine and rituximab (FR). Complete remission rates of approximately 47 and 70 percent are seen in patients treated with FR or FCR, respectively [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/4\">",
"      4",
"     </a>",
"     ]. Complete remission means that, for three months after treatment ends, the person has no signs or symptoms of their disease.",
"    </p>",
"    <p>",
"     Other physicians may recommend treatment with alemtuzumab, bendamustine, or chlorambucil. Neither alemtuzumab nor bendamustine have been directly compared to fludarabine in trials therefore it is difficult to know which may be more effective. The choice between treatment regimens is an individual-based decision made by balancing patient characteristics and drug side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Duration of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment with FCR or FR is usually given every day for five days, followed by no treatment for 23 days. Typically, six cycles of this treatment are given. However, treatment may be stopped sooner if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Symptoms do not improve",
"      </li>",
"      <li>",
"       Intolerable side effects develop",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     Most people with chronic lymphocytic leukemia who undergo chemotherapy treatment respond initially, but then develop relapsed disease at some point after treatment ends. A small number of patients do not respond to chemotherapy at all; this is called refractory disease. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"      \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Relapsed",
"     </span>",
"     &nbsp;&mdash;&nbsp;If relapse occurs six or more months after treatment ends, it is often possible to successfully use the same chemotherapy regimen again or use another chemotherapy treatment. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Chemotherapy'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Refractory",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a person's disease is refractory or relapses sooner than six months after treatment ends, the options for treatment are limited. Depending upon the individual's situation, the following options should be discussed with a physician:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Participation in a clinical trial",
"      </li>",
"      <li>",
"       Hematopoietic stem cell (also called bone marrow) transplantation",
"      </li>",
"      <li>",
"       Treatment with alternate chemotherapy regimens",
"      </li>",
"      <li>",
"       Treatment to reduce chronic lymphocytic leukemia-related symptoms and complications",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Removal of the spleen",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of people with chronic lymphocytic leukemia will develop a very enlarged spleen. While this often responds to treatment with chemotherapy or radiation, removal of the spleen is more likely to provide longer lasting benefits, including increases in red blood cell and platelet counts [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Bone marrow transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bone marrow transplantation (also called hematopoietic cell transplantation) is being more seriously considered as a therapy for CLL, especially for patients under age 55. If bone marrow transplantation is performed, it is usually done after treatment with chemotherapy. Giving chemotherapy often induces a complete or partial remission. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"      \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Bone marrow transplantation is a treatment in which the patient is given high doses of chemotherapy or radiation. This kills cancer cells but also destroys all normal cells developing in the bone marrow. After the treatment, the patient needs to have a healthy supply of very young blood cells, called stem cells, reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There are two main types of stem cell transplant: allogeneic and autologous.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Allogeneic transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;In allogeneic transplant, the patient is given stem cells from a donor, ideally a brother or sister with a similar genetic make-up. If the patient doesn't have a \"matched\" sibling, an unrelated person with a partially matched genetic makeup may be used.",
"    </p>",
"    <p>",
"     Patients who are unable to tolerate high dose chemotherapy may be candidates for a reduced intensity transplant (called a mini-transplant or non-myeloablative transplant) from a relative or a matched unrelated donor, and may achieve long term control of their CLL. Studies using non-myeloablative allogeneic transplants have shown significant promise, even in patients with relatively high risk or refractory disease [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Autologous transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;In autologous transplantation, the patient's own stem cells are removed before the high dose chemotherapy or radiation is given. Because the potential for cure with autologous transplantation is low for people with CLL, it is not usually recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The major complications of chronic lymphocytic leukemia are caused by the low blood counts and immune system problems that either arise from the disease itself or the treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infection is one of the most serious risks of treatment of chronic lymphocytic leukemia, accounting for approximately 50 percent of deaths. The most common infections affect the upper respiratory tract (sinuses, bronchi).",
"    </p>",
"    <p>",
"     Infection is often related to low levels of infection fighting proteins called gamma globulins. For this reason, patients who have repeated infections may be treated with intravenous immune globulin (IGIV, IVIG) every three to four weeks to decrease the chance of infection.",
"    </p>",
"    <p>",
"     Patients treated with certain chemotherapy agents can develop low white blood cell counts, which increases the risk of infections. In some cases, medications that promote the growth of new blood cells may be given to boost the white cell count and decrease the infection risk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Anemia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anemia, or low red blood cell counts, is common in chronic lymphocytic leukemia. Red blood cells are needed to carry oxygen to all the cells in the body. Patients with anemia may experience fatigue, weakness, and chest pain. Treatment options include blood transfusion and use of a medicine called erythropoietin, which can boost the red cell count in patients with certain types of anemia. Other forms of anemia may be treated with glucocorticoids (also called steroids).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Low platelet counts",
"     </span>",
"     &nbsp;&mdash;&nbsp;Platelets are important components of the blood's clotting mechanism. Without adequate numbers of platelets, internal and external bleeding can occur. Patients with chronic lymphocytic leukemia and low platelet counts may see their counts improve with treatment of the CLL. In some cases, platelet transfusions are needed. Removal of the spleen or use of steroids or other treatments that suppress the immune response (as part of the treatment for CLL) usually improves the platelet counts.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Psychological aspects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with chronic lymphocytic leukemia are forced to live with the uncertainties associated with a chronic illness. It can be puzzling and frightening to hear that you have leukemia and that no treatment is recommended. You and your healthcare providers must speak frequently and honestly to deal with any fears and clarify any misunderstandings about this sometimes confusing disease. Some patients and families benefit from psychological counseling to help them cope with the strong emotions that can accompany this diagnosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Many patients with leukemia will be asked about enrolling in a clinical (research) trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask your doctor for more information, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://cancernet.nci.nih.gov/clinicaltrials\">",
"        file://cancernet.nci.nih.gov/clinicaltrials",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498614499\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20478602\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=see_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20478616\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H33\">",
"     <span class=\"h3\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=see_link\">",
"      Evaluating response to treatment of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/pdq/treatment/CLL/patient/\">",
"      www.cancer.gov/cancertopics/pdq/treatment/CLL/patient/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      file://www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"      www.leukemia-lymphoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Marrow Donor Program",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marrow.org/\">",
"      www.marrow.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Eastern Cooperative Oncology Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://ecog.dfci.harvard.edu/general/intro.html\">",
"      file://ecog.dfci.harvard.edu/general/intro.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Southwest Oncology Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.swog.org/Patients/Index.asp\">",
"      www.swog.org/Patients/Index.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/10/6309/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/10/6309?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6309/abstract/1\">",
"      Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6309/abstract/2\">",
"      Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6309/abstract/3\">",
"      Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6309/abstract/4\">",
"      Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989; 110:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6309/abstract/5\">",
"      Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6309/abstract/6\">",
"      Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_10_6309=[""].join("\n");
var outline_f6_10_6309=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CHRONIC LYMPHOCYTIC LEUKEMIA OVERVEIW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           STAGING OF CHRONIC LYMPHOCYTIC LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           MANAGEMENT OF ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TREATMENT OF LOCALIZED CHRONIC LYMPHOCYTIC LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           TREATMENT OF ADVANCED OR SYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H32\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/55/24439\" title=\"figure 1\">",
"           Lymph nodes body PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_10_6310="Proctocolectomy extraction via perineum";
var content_f6_10_6310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Proctocolectomy extraction via perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the extraction of the total proctocolectomy through the perineum. This procedure was performed laparoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6310=[""].join("\n");
var outline_f6_10_6310=null;
var title_f6_10_6311="Myasthenic crisis";
var content_f6_10_6311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myasthenic crisis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6311/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/10/6311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenic crisis is a life-threatening condition, which is defined as weakness from acquired myasthenia gravis (MG) that is severe enough to necessitate intubation or to delay extubation following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/1\">",
"     1",
"    </a>",
"    ]. The respiratory failure is due to weakness of respiratory muscles.",
"   </p>",
"   <p>",
"    Severe bulbar (oropharyngeal) muscle weakness often accompanies the respiratory muscle weakness, or may be the predominant feature in some patients. When this results in upper airway obstruction or severe dysphagia with aspiration, intubation and mechanical ventilation are necessary.",
"   </p>",
"   <p>",
"    This topic will review the evaluation and treatment of myasthenic crisis and rapidly worsening MG. Other aspects of MG are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRECIPITANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenic crisis may be precipitated by a variety of factors, most often a concurrent infection. It can also follow a surgical intervention, pregnancy, childbirth, or tapering of immunosuppressive medications. In addition, myasthenic crisis can occur spontaneously as part of the natural history of myasthenia gravis (MG) itself. A number of drugs can increase the weakness in myasthenia (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"     table 1",
"    </a>",
"    ) and should be considered as possible precipitants in this setting. This is of more concern with certain antibiotics (aminoglycosides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ), cardiac drugs (beta-blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ), and magnesium.",
"   </p>",
"   <p>",
"    A potential major side effect of excessive anticholinesterase medication is weakness, which can be difficult to distinguish from worsening MG. This paradoxical weakening with anticholinesterase medications is called \"cholinergic crisis.\" However, cholinergic crisis is rarely if ever seen with dose limitation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    to less than 120 mg every three hours. Cholinergic crisis is so rare that it should not be the presumed cause of increasing weakness unless the doses taken are known to significantly exceed this range. Otherwise, even in the presence of cholinergic side effects, it should be assumed that the patient's underlying MG is worsening and appropriate treatment should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop myasthenic crisis typically experience increasing generalized weakness, particularly bulbar, as a warning. Occasionally, a patient presents with respiratory insufficiency out of proportion to his or her limb or bulbar weakness.",
"   </p>",
"   <p>",
"    There are a number of general concepts common to the treatment of myasthenic crisis (",
"    <a class=\"graphic graphic_table graphicRef82137 \" href=\"UTD.htm?34/39/35451\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Patients with severe or rapidly increasing generalized weakness secondary to an exacerbation of MG should be admitted to an intensive care unit (ICU). This is particularly important for those patients at risk for respiratory failure. Symptoms and signs that should alert the clinician include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspnea that occurs, or worsens, when the patient lies supine",
"     </li>",
"     <li>",
"      Severe dysphagia with difficulty clearing secretions",
"     </li>",
"     <li>",
"      Signs of respiratory muscle weakness, such as hypophonia, pausing during speech to take a breath, increased respiratory rate, use of accessory muscles of respiration, and paradoxical abdominal breathing",
"     </li>",
"     <li>",
"      Low baseline vital capacity (less than 30",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of ideal body weight), even if the patient is breathing without distress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intercurrent infections are often a contributing factor and should be sought out and treated aggressively, and any factors that may have precipitated or exacerbated the patient's weakness should be sought and corrected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RESPIRATORY CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessment of function",
"    </span>",
"    &nbsp;&mdash;&nbsp;One particular danger in myasthenic crisis is that the generalized weakness can mask the usual signs of respiratory distress, such as accessory muscle use. In addition, weak respiratory muscles may suddenly fatigue, producing precipitous respiratory collapse. On the other hand, some patients have weakness of the respiratory muscles that is out of proportion to the weakness in other skeletal muscles. In rare cases of myasthenic crisis, ventilatory failure is the only clinically overt manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When increasing muscle weakness becomes apparent, certain tests of respiratory muscle strength may help to identify impending respiratory failure and allow elective rather than emergent intubation. The vital capacity (VC) and the maximal inspiratory force (MIF) are the main respiratory parameters to monitor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/2,4,7,8\">",
"     2,4,7,8",
"    </a>",
"    ]. The maximal expiratory pressure (MEP) assesses strength of the expiratory muscles that are important for effective cough.",
"   </p>",
"   <p>",
"    The VC reflects the mechanical function of both inspiratory and expiratory respiratory muscles and can be easily performed at the bedside to assess the patient's trend. The patient is instructed to take a deep breath in and then to exhale maximally into a spirometer. The VC should be measured frequently, as often as every two hours in some cases, but typically every four hours. Some experts recommend assessing both supine and sitting VC, as diaphragmatic weakness is more apparent on the supine measurement. However, the predicted values of VC are based on measurements in the sitting position. The maximal inspiratory force (MIF) provides similar information.",
"   </p>",
"   <p>",
"    The VC and MIF are the most useful measures of respiratory muscle involvement in myasthenic crisis. Neither measurement has been shown to be superior, so the two measures are usually analyzed in combination. In most patients, they help determine the need for and timing of elective endotracheal intubation. However, patients with myasthenia gravis (MG) may precipitously fatigue with the rapid development of respiratory failure before a downward trend in VC is noted. On the other hand, there are some patients with facial weakness caused by MG who cannot make a good seal with the mask and have a falsely low VC. Thus, the VC and MIF should always be interpreted in the context of the clinical symptoms and signs of respiratory muscle involvement, as well as the trend in these measures.",
"   </p>",
"   <p>",
"    Oxygenation should be monitored continuously, although abnormalities of arterial blood gases (eg, hypoxemia and hypercarbia) are insensitive measures of respiratory muscle weakness because they often are a late abnormality occurring only after the onset of life-threatening respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/2,4,7,8\">",
"     2,4,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Elective intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With close monitoring of the patient's condition (the VC, MIF,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MEP), endotracheal intubation can often be performed as an elective procedure rather than as an emergent response to precipitous respiratory collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Should the need for emergent intubation develop,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    is safe in myasthenia gravis, but increased doses are needed. The techniques and medications for rapid sequence intubation in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link&amp;anchor=H5#H5\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\", section on 'Clinical use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elective intubation should be considered if serial measurements of the VC show values less than 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    or if the MIF is worse than -30 cmH20. Ventilatory assistance should consist of endotracheal intubation with positive pressure mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After intubation, cholinesterase inhibitor therapy is usually temporarily withdrawn to avoid the excess secretions that may complicate pulmonary management. These agents can be reintroduced after successful extubation and dysphagia has largely resolved.",
"   </p>",
"   <p>",
"    Meticulous attention to pulmonary toilet is required because of an ineffective cough mechanism. In a retrospective study, \"aggressive\" respiratory treatment, comprising the use of suction, intermittent positive-pressure breathing or bronchodilator treatments, sighs, and chest physiotherapy, appeared to decrease the risk of prolonged respiratory complications compared with historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/9\">",
"     9",
"    </a>",
"    ]. This observation needs to be validated in a prospective study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RAPID THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis and intravenous immune globulin (IVIG) start to work within several days, but the benefits last only a few weeks (",
"    <a class=\"graphic graphic_table graphicRef68178 \" href=\"UTD.htm?9/19/9531\">",
"     table 3",
"    </a>",
"    ). In most patients, initiation of high-dose glucocorticoids is also necessary, since the therapeutic effect of plasmapheresis or IVIG is short-lived, and lasts only weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis (plasma exchange) directly removes acetylcholine receptor antibodies from the circulation, and its clinical efficacy roughly correlates with the reduction in antibody levels. The supportive evidence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of myasthenia gravis\", section on 'Plasmapheresis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasmapheresis is an established treatment for seriously ill patients in the midst of myasthenic crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], although it has never been studied in a randomized, controlled trial for this indication. The beneficial clinical effect usually lasts only three to four weeks. In addition, the acetylcholine receptor antibody levels rebound within weeks if no concurrent immunotherapy (eg, glucocorticoids) is used.",
"   </p>",
"   <p>",
"    A typical course of treatment consists of five exchanges (3 to 5 L of plasma each) over 7 to 14 days. Although performed daily in some circumstances, exchanges done every other day are probably more effective in reducing the antibody levels due to the time it takes for the extravascular immunoglobulin to regain equilibrium after each exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) is used in the same setting as plasmapheresis to quickly reverse an exacerbation of myasthenia. IVIG is the pooled immunoglobulins from thousands of donors and acts in myasthenia via uncertain mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles in the use of immune globulin\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The total dose of IVIG is 2",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    usually over two to five days (eg, 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day over five days). However, there are only limited data directly comparing different IVIG doses for the treatment of myasthenia gravis (MG) exacerbations or crisis. One clinical trial involving 173 patients with acute exacerbation of MG found no significant difference in the primary outcome measure (the myasthenic muscular score) after IVIG 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (given as 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    on two consecutive days) compared with IVIG 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (given as 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    on day one and placebo on day two) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/13\">",
"     13",
"    </a>",
"    ]. The investigators concluded that IVIG 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    administered in a single dose may be the optimal IVIG dose, given the high cost of IVIG infusions.",
"   </p>",
"   <p>",
"    Spreading the IVIG dose over more days may be preferable in those who have renal disease or heart failure, and in those who are elderly.",
"   </p>",
"   <p>",
"    Like plasmapheresis, IVIG has never been compared directly against placebo in a randomized, controlled trial for treatment of myasthenic crisis. Data supporting the use of IVIG in patients with MG outside of the setting of myasthenic crisis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of myasthenia gravis\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choosing rapid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data comparing the two rapid therapies for treatment of myasthenic crisis, and the available evidence has not shown a significant advantage for either.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Myasthenia Gravis Clinical Study Group trial randomly assigned 87 patients with severe clinical exacerbation of MG to treatment with IVIG or plasmapheresis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/11\">",
"       11",
"      </a>",
"      ]. About 50 percent of the patients reached the target 20 point improvement on the myasthenia muscle score by day nine in the plasmapheresis group and day 12 in the IVIG group. However, there were no functional or strength differences in the two treatment groups at day 15, and the rate of adverse events was lower in the IVIG group.",
"     </li>",
"     <li>",
"      Similarly, a systematic review comparing trials of plasmapheresis versus IVIG found no convincing difference in the beneficial effects of these therapies for treating exacerbation or worsening of MG [",
"      <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective series of 54 patients in myasthenic crisis found plasmapheresis to be superior to IVIG [",
"      <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/12\">",
"       12",
"      </a>",
"      ]. The study reported a more prominent clinical improvement (scored by a uniform scheme) one week after initiation of treatment with plasmapheresis than with IVIG, even though patients in the plasmapheresis group had only received three or four treatments, while the IVIG group had completed the five treatments.",
"     </li>",
"     <li>",
"      An observational report identified 1606 patients admitted for the treatment of MG from an administrative database [",
"      <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/15\">",
"       15",
"      </a>",
"      ]. Among the 698 patients with myasthenic crisis, those treated with plasma exchange (n = 529) had significantly higher mortality and complication rates than those treated with IVIG (n = 169). However, the strength of this finding is limited by the observational nature of this study, which does not exclude possible selection bias (eg, sicker patients were more likely to be treated with plasma exchange). Among the whole group of myasthenics, the adjusted mortality and complication rates were not significantly different between the two treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the trials do not show a clear difference between IVIG and plasmapheresis in the treatment of myasthenia exacerbations or crisis, there is suggestive evidence and personal clinical experience that plasmapheresis works more quickly than IVIG in seriously ill patients with myasthenia. Most neuromuscular experts still prefer plasmapheresis as a first-line therapy for myasthenic crisis, in part because the onset of action appears to be more rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. However, others prefer IVIG because it is easier to administer and has a lower incidence of serious side effects, but similar efficacy, compared with plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMUNOMODULATING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the therapeutic effect of plasmapheresis, or intravenous immune globulin (IVIG), is short-lived and lasts only weeks, glucocorticoids are generally started at high dose (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60 to 80 mg daily). The onset of benefit in patients with myasthenia gravis (MG) generally begins within two to three weeks and peaks after a mean of 5.5 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initiation of high-dose glucocorticoids is associated with a transient worsening of weakness and myasthenic symptoms that is serious in up to 50 percent and associated with respiratory failure requiring mechanical ventilation in up to 10 percent. The transient worsening usually occurs 5 to 10 days after the initiation of glucocorticoids and lasts about five or six days. However, concern regarding initial worsening of MG with high-dose glucocorticoids is ameliorated when the patient is receiving concurrent treatment with plasmapheresis or IVIG. The quick onset of action of these rapid therapies helps to prevent the transient worsening that would otherwise occur due to the glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other immunomodulating treatments for MG, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , can be considered if glucocorticoids are contraindicated or if an inadequate therapeutic response has been observed with glucocorticoids. However, these agents have a delayed onset of action compared with glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"     table 4",
"    </a>",
"    ). These agents are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     WEANING FROM VENTILATORY SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate weaning of mechanical ventilation should be individualized for each patient. Generally, weaning should only be initiated after the patient has started treatment with plasmapheresis or intravenous immune globulin (IVIG).",
"   </p>",
"   <p>",
"    Weaning should proceed once the patient shows evidence of improving respiratory muscle strength, with a vital capacity (VC) &gt;15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    and a maximal inspiratory force (MIF) more negative than 30 cmH2O. In the absence of significant parenchymal lung disease, one clinical rule of thumb is that the recovering patient with myasthenia is ready to wean when he or she can hold the head off the bed. There are currently no published data to suggest that any of the several approaches to discontinuing mechanical ventilation is clearly the preferred method in these patients. The clinician's experience and individual patient characteristics must therefore guide decisions about the choice of the initial weaning strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the approach used, weaning should proceed in a manner that prevents respiratory muscle fatigue and allows for adequate rest between weaning trials. In one series, extubation failure occurred frequently in patients in myasthenic crisis (44 percent) and reintubation was required in 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/20\">",
"     20",
"    </a>",
"    ]. Lower VC at the time of extubation, atelectasis, and need for bilevel positive airway pressure (BPAP) ventilation after extubation predicted the need for reintubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With advances in therapy and intensive care management, the prognosis in myasthenic crisis has dramatically improved over the last four decades from a mortality rate of 75 percent to the current rate of &le;5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/2,15,21\">",
"     2,15,21",
"    </a>",
"    ]. However, it is still associated with substantial morbidity. As an example, a 1997 review found a mean duration of two weeks on a ventilator, similar to the duration of mechanical ventilation reported in a prior review of myasthenic crisis at the same institution in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6311/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=see_link\">",
"       \"Patient information: Myasthenia gravis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenic crisis is a life-threatening condition, and it is characterized by neuromuscular respiratory failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenic crisis may be precipitated by a variety of factors including infection, surgery, or tapering of immunosuppression. Often, the crisis occurs as a spontaneous event. A number of medications can increase the weakness in myasthenia (",
"      <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"       table 1",
"      </a>",
"      ) and should also be considered as possible precipitants. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Precipitants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with moderate to severe exacerbations of myasthenia who are deteriorating should be admitted to an intensive care setting so they can be closely monitored (",
"      <a class=\"graphic graphic_table graphicRef82137 \" href=\"UTD.htm?34/39/35451\">",
"       table 2",
"      </a>",
"      ). Vital capacity (VC)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      maximal inspiratory force (MIF) should be measured frequently, as often as every two hours in some cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest elective intubation when the VC is &lt;20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      body weight or when the maximal inspiratory force (MIF) is less negative than -30 cmH2O, or when clinical signs of respiratory distress are present (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Elective intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest withdrawal of anticholinesterase medications in patients who are intubated to reduce airway secretions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These medications can be restarted at a low dose after the patient has shown a response to plasmapheresis or intravenous immune globulin (IVIG). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Elective intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend rapid therapy with plasmapheresis or IVIG to treat patients with rapidly worsening myasthenia gravis (MG) or myasthenic crisis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef68178 \" href=\"UTD.htm?9/19/9531\">",
"       table 3",
"      </a>",
"      ). We suggest the use of plasmapheresis over IVIG for most patients with severe MG or myasthenic crisis because it has a slightly more rapid onset of action (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rapid therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend concurrent initiation of chronic immunomodulating therapy with rapid therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), anticipating that the chronic immunotherapy will provide benefit for MG after the transient benefit of the rapid therapy has dissipated (",
"      <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"       table 4",
"      </a>",
"      ). The choice of specific agent &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      &mdash; depends on many factors. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"       \"Chronic immunomodulating therapies for myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest weaning from mechanical ventilation after the patient has started treatment with plasmapheresis or IVIG and the patient shows evidence of improving respiratory muscle strength (VC &gt;15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      and MIF better than -30 cm H2O) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Weaning from ventilatory support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognosis in myasthenic crisis has substantially improved over the decades, but it is still associated with substantial morbidity and a mortality rate of &le;5 percent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/1\">",
"      Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis 2002; 4:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/2\">",
"      Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004; 24:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/3\">",
"      Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007; 261:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/4\">",
"      Chaudhuri A, Behan PO. Myasthenic crisis. QJM 2009; 102:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/5\">",
"      Mier A, Laroche C, Green M. Unsuspected myasthenia gravis presenting as respiratory failure. Thorax 1990; 45:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/6\">",
"      Dushay KM, Zibrak JD, Jensen WA. Myasthenia gravis presenting as isolated respiratory failure. Chest 1990; 97:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/7\">",
"      Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol 2003; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     Bird, SJ, Teener, JW. Acute neuromuscular weakness. In: The Intensive Care Unit Manual, Lanken, PN, Hanson, CW, Manaker, S (Eds), W.B. Saunders, Philadelphia, 2001. p.755.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/9\">",
"      Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med 2002; 30:2663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/10\">",
"      Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/11\">",
"      Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/12\">",
"      Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/13\">",
"      Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005; 62:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/14\">",
"      Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012; 12:CD002277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/15\">",
"      Mandawat A, Kaminski HJ, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010; 68:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/16\">",
"      Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/17\">",
"      Gilhus NE. Neuromuscular disease: acute treatment for myasthenia gravis. Nat Rev Neurol 2011; 7:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/18\">",
"      Sathasivam S. Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag 2011; 7:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/19\">",
"      Sathasivam S. Evidence for use of intravenous immunoglobulin and plasma exchange in generalised mysasthenia gravis. Adv Clin Neurosci Rehabil 2009; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/20\">",
"      Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Predictors of extubation failure in myasthenic crisis. Arch Neurol 2008; 65:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/21\">",
"      Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6311/abstract/22\">",
"      Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48:1253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5125 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6311=[""].join("\n");
var outline_f6_10_6311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRECIPITANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RESPIRATORY CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessment of function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Elective intubation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RAPID THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choosing rapid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMUNOMODULATING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      WEANING FROM VENTILATORY SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12254\" title=\"table 1\">",
"      Drugs that may worsen MG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/39/35451\" title=\"table 2\">",
"      Rx myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/19/9531\" title=\"table 3\">",
"      Rapid rx myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/56/5004\" title=\"table 4\">",
"      Therapies for MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=related_link\">",
"      Chronic immunomodulating therapies for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=related_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_10_6312="Endoscope disinfection";
var content_f6_10_6312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscope disinfection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6312/contributors\">",
"     George W Meyer, MD, FACP, MACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6312/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6312/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/10/6312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although endoscopic equipment has been implicated in transmitting infection, it appears as if virtually all transmissions have been due to errors in the process of cleaning and disinfecting the equipment or in breakdown of general infection control practices [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As an example, the Department of Veterans Affairs in the United States discovered potential infections that may have been caused by failure to clean the accessory rinsing devices for the auxiliary water channel (MAJ-855 and MH-974) that came with newer scopes. (",
"    <a class=\"external\" href=\"file://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM\">",
"     www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will discuss infectious agents that can potentially be transmitted during gastrointestinal endoscopy and outline the recommendations from various societies for the cleaning and disinfection of gastrointestinal endoscopes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71945044\">",
"    <span class=\"h1\">",
"     RISK OF INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus has been transmitted to a single person following endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/4\">",
"     4",
"    </a>",
"    ]. A woman who had an endoscopy one day after a patient with known chronic hepatitis B developed hepatitis B infection 96 days following the procedure and recovered uneventfully. Other patients who underwent endoscopy with the same endoscope three, four, and five days after the initial endoscopy did not develop hepatitis B. At the time (1980), endoscopes could not be totally immersed in fluid and the",
"    <span class=\"nowrap\">",
"     air/water",
"    </span>",
"    channel was not specifically treated with glutaraldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/2\">",
"     2",
"    </a>",
"    ]. Scopes have been engineered to be less complicated and are easier to clean since the 1980s. Several reports before and after 1980 suggest that with proper cleaning and disinfection, hepatitis B is adequately removed from endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of hepatitis C, an RNA virus, during endoscopy has been demonstrated in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Transmission occurred following colonoscopy in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/8\">",
"     8",
"    </a>",
"    ], and after ERCP in another [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/10\">",
"     10",
"    </a>",
"    ]. The endoscope responsible for transmitting infection in the two patients infected following colonoscopy had not undergone the recommended duration of disinfection, and the biopsy forceps, the likely source of the infection, had been cleaned but not sterilized [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/9\">",
"     9",
"    </a>",
"    ]. An increased prevalence of hepatitis C transmission in patients who had undergone endoscopic biopsies has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proper disinfection of endoscopes contaminated with hepatitis C virus can effectively eliminate the risk of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one report, there were no cases of proven transmission of hepatitis C when endoscopes were processed using current ASGE guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;No case of HIV transmission by endoscopy has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/15\">",
"     15",
"    </a>",
"    ]. Exposure to 2 percent solution of glutaraldehyde for two minutes completely inactivates the HIV virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Other approved agents also kill the HIV virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hierarchy of relative resistance to cleaning and disinfection, vegetative bacteria such as Pseudomonas sp. and Salmonella sp. are the most susceptible to disinfectants, while the mycobacteria are less susceptible and bacterial spores (from B. subtilis and C. difficile) are the most difficult to eliminate. Although salmonella and pseudomonas are ubiquitous and have been associated most frequently with endoscopic transmission, they are both sensitive to multiple agents, including glutaraldehyde, phenols, and iodophors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;While mycobacteria transmission has been associated with bronchoscopy, there are no reports of mycobacteria infection following gastrointestinal endoscopy. Peracetic acid eliminates mycobacteria from bronchoscopes, colonoscopes, and endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/20\">",
"     20",
"    </a>",
"    ]. Simulated use testing showed that a 6-log reduction of Mycobacterium tuberculosis eradication is achieved from all specimens after 10 minutes of glutaraldehyde exposure at room temperature followed by an alcohol rinse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/21\">",
"     21",
"    </a>",
"    ]. The same group demonstrated that commercially available high-level disinfectants such as Cidex (2 percent glutaraldehyde) for 20 minutes at 20&ordm;C, Sporox (7.5 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    ) for 30 minutes at 20&ordm;, and Steris 20 (0.2 percent peracetic acid) for 12 minutes at 50 to 56&ordm; are equally effective when used in simulated use testing in conjunction with cleaning and in accordance with recommended guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/22\">",
"     22",
"    </a>",
"    ]. However, Mycobacterium avium-intracellulare is particularly resistant and requires extra exposure times [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that H. pylori was extremely sensitive to the usual chemicals used in high-level disinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/24\">",
"     24",
"    </a>",
"    ]. The risk of transmission by endoscopy appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization classifies saliva, gingival tissue, intestinal tissue, feces, and blood as having no detectable infectivity for prions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/26\">",
"     26",
"    </a>",
"    ]. In a draft statement, the Centers for Disease Control and Prevention (CDC) concluded that current guidelines for cleaning and disinfecting instruments were adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/27\">",
"     27",
"    </a>",
"    ]. Although prions are incredibly resistant to most methods of sterilization, no reported case of prion-related disease has been transmitted by endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link\">",
"     \"Diseases of the central nervous system caused by prions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study found that exposure to a temperature of 134&ordm;C for 3.5 minutes was necessary for",
"    <span class=\"nowrap\">",
"     decontaminating/sterilizing",
"    </span>",
"    of prion-contaminated materials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/30\">",
"     30",
"    </a>",
"    ]. A properly functioning moist-heat sterilizer with adequate active air removal is required and aldehyde use is contraindicated since it does not reliably kill prions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     Guanidine",
"    </a>",
"    thiocyanate solutions are highly effective against prions and may be useful in the proper settings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/32\">",
"     32",
"    </a>",
"    ]. Other treatments recommended by the World Health Organization include soaking in 1N NaOH (one hour at 20&ordm;C), soaking in 12.5 percent bleach (one hour at 20&ordm;C), and steam sterilization in an autoclave (134 to 138&ordm;C for 18 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/31\">",
"     31",
"    </a>",
"    ]. Some endoscopy units dedicate a set of endoscopes for patients with known prion disease, although the cost of this practice is likely prohibitive and alternative diagnostic modalities (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, use of a sheathed endoscope) should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENDOSCOPE REPROCESSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1968 Spaulding proposed classifying medical devices into three groups according to the risk of infection related to their use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Critical devices are those that enter sterile tissue or vascular spaces (eg, biopsy forceps, papillotomy devices). These devices should be sterilized.",
"     </li>",
"     <li>",
"      Semicritical devices are those that contact the mucous membranes (eg, upper and lower gastrointestinal endoscopes). These devices require high-level disinfection designed to destroy all microorganisms except some bacterial spores.",
"     </li>",
"     <li>",
"      Noncritical devices only contact skin (eg, blood pressure cuffs) and need not be sterilized or subjected to high-level disinfection procedures. These items do require cleaning with low-level disinfection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastrointestinal endoscopes meet the definition of semicritical devices. Thus, most organizations, including the Centers for Disease Control and Prevention (CDC), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA), recommend high-level disinfection (HLD) as appropriate for these instruments. A multi-society position statement for endoscope reprocessing has been published, the contents of which are reflected in the subsequent discussions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"     34",
"    </a>",
"    ]. A guideline has also been issued by the World Organization of Gastroenterology (",
"    <a class=\"external\" href=\"file://www.omed.org/downloads/pdf/guidelines/wgo_omed_endoscope_disinfection.pdf\">",
"     www.omed.org/downloads/pdf/guidelines/wgo_omed_endoscope_disinfection.pdf",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thorough training of personnel is the first critical step in endoscope cleaning and disinfection. Staff must be properly trained and understand all aspects of handling all pieces of equipment. Training manuals and competency validation are key components to staff training [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscope reprocessing can be divided into six separate stages: precleaning, leak testing, cleaning, high-level disinfection, rinsing, and drying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Precleaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important part of endoscope preparation is proper cleaning, which must be started promptly after procedure completion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The most important part of this preparation is immediate washing of the exterior of the insertion tube with enzymatic detergent solution and suctioning of this solution alternating with air through the",
"    <span class=\"nowrap\">",
"     biopsy/suction",
"    </span>",
"    channel until the fluid is clear of all debris. The",
"    <span class=\"nowrap\">",
"     air/water",
"    </span>",
"    channel should be purged to clear debris from the channel. This action prevents the debris from drying on surfaces and removes large numbers of microorganisms. After these steps have been completed the instrument is ready to be transferred to the processing area in an enclosed container [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Leak testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leak testing should be performed according to the manufacturer's instructions before submerging the scope into reprocessing solution to minimize damage to scope parts. The manufacturer's instructions should include guidelines on what to do if a leak is detected or if the scope appears to be damaged [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cleaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cleaning is a critical step that must be done properly prior to disinfection whether disinfection is performed manually or by machine. When properly performed, it reduces the endoscope's mycobacterial load by &gt;4 log10 (99.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/36\">",
"     36",
"    </a>",
"    ]. A fresh detergent solution should be used for each endoscope to prevent cross contamination. The detergent should be low sudsing and diluted according to the manufacturer's instructions.",
"   </p>",
"   <p>",
"    The scope should be immersed and all debris washed from its exterior by wiping and brushing. The scope should remain immersed during the cleaning process. The suction and",
"    <span class=\"nowrap\">",
"     air/water",
"    </span>",
"    valves, the biopsy channel cover, the distal end hood (if present), and all other removable parts should be detached while parts not intended for reuse should be discarded [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ]. Brushing should continue until there is no debris visible on the brush. Cleaning adapters should be attached (note that elevator channels have small lumens that require manual reprocessing using a 2.5 mL syringe). Ultrasonic cleaning of reusable accessories and endoscope components can be used to remove soil and organic material from areas that are difficult to clean [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"     34",
"    </a>",
"    ]. Reusable brushes should be cleaned using high-level disinfectant between cases. The reusable brushes should be inspected between uses and replaced when worn, frayed, bent, or otherwise damaged. Worn bristles are ineffective for cleaning, while damaged brushes can damage endoscope channels.",
"   </p>",
"   <p>",
"    All channels should be filled with detergent solution. Prolonged soaking of the channels in the cleaning solution may be beneficial if there has been a delay in initiation of the cleaning process [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ]. The scope and all reusable parts should be rinsed with clean water to remove debris and detergent. The American Society of Gastrointestinal Endoscopy recommends \"water filtered through 0.2 micron filter or otherwise treated by a method documented to improve the microbiological quality of the water\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/39\">",
"     39",
"    </a>",
"    ]. Enzymatic detergents should be discarded after each use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"     34",
"    </a>",
"    ]. The water bottle (used for cleaning the lens and for irrigation) and its connecting tube should undergo high-level disinfection or sterilization at least daily. In addition, it should be filled with sterile water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Automatic washer-disinfector",
"    </span>",
"    &nbsp;&mdash;&nbsp;When using an automatic washer-disinfector (AEWD) it is important to be sure that the endoscope and its components can be effectively reprocessed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"     34",
"    </a>",
"    ]. Some parts (the elevator wire channel of duodenoscopes, for example) are not effectively disinfected by most models, and require manual disinfection. The endoscope and its components must be placed into the AEWD according to the manufacturer's instructions. High-level disinfection or sterilization cannot be assured if the cycle is interrupted. Advisories from the Food and Drug Administration should be reviewed regularly for reports of specific AEWD deficiencies. The American Society for Gastrointestinal Endoscopy has published a summary of chemical germicides and automatic endoscopic reprocessors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2009, the Food and Drug Administration (FDA) announced that because STERIS Corporation (STERIS) has significantly modified its SS1 processor, it no longer had FDA approval [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/41\">",
"     41",
"    </a>",
"    ]. The FDA has not approved or cleared the modified product and has not determined whether the SS1 is safe or effective for its labeled claims, including claims that it sterilizes medical devices.",
"   </p>",
"   <p>",
"    The announcement from the FDA pertains to all SS1 systems, regardless of when they were manufactured or the model.",
"   </p>",
"   <p>",
"    The FDA has asked healthcare facilities to take voluntary action to transition these products to legally-marketed products and does not recommend that procedures be interrupted during this transition period.",
"   </p>",
"   <p>",
"    The FDA made the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If you have an acceptable alternative to the SS1 to meet your sterilization and disinfection needs, you should transition to that alternative as soon as possible to ensure continued patient safety.",
"     </li>",
"     <li>",
"      If you do not have an acceptable alternative to the SS1, you should promptly assess your facility's patient-care needs and sterilization and disinfection requirements and take steps to obtain legally-marketed substitutes for the SS1.",
"     </li>",
"     <li>",
"      The FDA does not recommend that facilities immediately stop using the device, but that they take voluntary steps to transition to legally-marketed alternatives promptly. The FDA initially expected that facilities should be able to make this transition over a three- to six-month time period, but on February 2, 2010, extended that time period to 18 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information is available at the FDA's website:",
"    <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices\">",
"     www.fda.gov/MedicalDevices/Safety/AlertsandNotices",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In April 2010, the FDA cleared the STERIS System 1E (SS1E) Liquid Chemical Sterilant Processing System, which is an alternative to the SS1 processor. The FDA notes that this processor should only be used with instruments that are compatible with the S40 sterilant and the SS1E processing system. A list of FDA approved alternatives to the SS1 processor can be found at:",
"    <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm194429.htm?zbrandid=439&amp;zidType=CH&amp;zid=4025763&amp;zsubscriberId=93262298&amp;zbdom=\">",
"     www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm194429.htm?zbrandid=439&amp;zidType=CH&amp;zid=4025763&amp;zsubscriberId=93262298&amp;zbdom=",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     High-level disinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many chemicals approved by the Food and Drug Administration (FDA) of the United States for use as high-level disinfectants in endoscope reprocessing, including glutaraldehyde, peracetic acid,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , peracetic",
"    <span class=\"nowrap\">",
"     acid/hydrogen",
"    </span>",
"    peroxide, and orthophthaldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/36,42-44\">",
"     36,42-44",
"    </a>",
"    ]. Peracetic acid is the only chemical approved for single use. The others may be reused; their strength should be tested by test strips to ensure the strengths remain above the minimum effective concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"     34",
"    </a>",
"    ]. The endoscope manufacturer's recommendations should be considered when choosing a disinfection solution since non-approved disinfection methods may void the manufacturer's warranty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glutaraldehyde",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two percent glutaraldehyde is the most widely used liquid chemical disinfectant. The ACG, ASGE, AGA, Society of Gastroenterology Nurses and Associates (SGNA), and the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) recommend that 20 minutes at 20&ordm;C is adequate to reduce bacterial levels by 6 logs if proper cleaning occurred prior to exposure to glutaraldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38,43\">",
"     38,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Peracetic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peracetic acid was introduced in the 1980s and is available in two concentrations: 0.2 and 0.35 percent. The 0.2 percent peracetic acid is designed for single use only and is used only in a dedicated processor (Steris I processor). Adequate sterilization can be achieved in 12 minutes at 50&ordm; to 55&ordm;C, although the manufacturer recommends 30 minutes at 50&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/42\">",
"     42",
"    </a>",
"    ]. As of September 2006, the 0.2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    did not have an indication for high-level disinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/44\">",
"     44",
"    </a>",
"    ]. The 0.35 percent product is not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hydrogen peroxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     Hydrogen peroxide",
"    </a>",
"    (7.5 percent) can provide the same high-level disinfection in 10 minutes at 20&ordm;C as 2 percent glutaraldehyde does at 20 minutes after manual disinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the manufacturer's recommended contact time for high-level disinfection is 30 minutes at 20&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/42\">",
"     42",
"    </a>",
"    ]. Hydrogen peroxide is not compatible with flexible gastrointestinal endoscopes manufactured by Olympus, Pentax, or Fujinon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Peracetic acid/hydrogen peroxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of three chemicals listed by some endoscope manufacturers as compatible with their instruments is a combination of 0.08 percent peracetic acid with 1 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . High-level disinfection is achieved after 25 minutes at 20&ordm;C. It has a maximum reuse time (the number of days that a product can be reused) of 21 days (compared to 14 days reuse time with 2 percent glutaraldehyde). (Note: Olympus does not endorse this product for use on any of its endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/42\">",
"     42",
"    </a>",
"    ].) Hydrogen peroxide is not compatible with flexible gastrointestinal endoscopes manufactured by Olympus, Pentax, or Fujinon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Orthophthaldehyde",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthophthaldehyde was FDA approved in late 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/39\">",
"     39",
"    </a>",
"    ]. It is more effective than glutaraldehyde against mycobacteria but less so against bacterial spores. High-level disinfection with 0.55 percent orthophthaldehyde is achieved in 12 minutes at 20&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ] or five minutes at 25&ordm;C, and increasing pH to 8 improves sporicidal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/45\">",
"     45",
"    </a>",
"    ]. Pentax and Fujinon list it as compatible with their endoscopes. Olympus lists it as compatible with all their endoscopes except the OSF and OSF-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Superoxidized water",
"    </span>",
"    &nbsp;&mdash;&nbsp;This compound is effective against spores and mycobacteria, including Mycobacterium avium intracellulare. It has great potential for endoscope cleaning but is not yet FDA approved [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chlorine dioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Freshly prepared chlorine dioxide rapidly destroys resistant organisms and spores and may be effective for up to 14 days if the material is properly stored in sealed containers with minimal air space above the surface [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/45\">",
"     45",
"    </a>",
"    ]. However, it is more damaging to scopes than glutaraldehyde. No endoscope manufacturer has completed compatibility testing yet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Quaternary ammonium compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quaternary ammonium compounds have deficiencies in their antibiotic spectrum and are not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Isopropyl alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isopropyl alcohol and quaternary ammonium compounds are low-level disinfectants and are not appropriate for endoscope disinfection; isopropyl alcohol does have an important use for endoscope drying. Isopropyl alcohol (70 percent) can be quite effective against most infectious agents but prolonged exposure can damage adhesives used in endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/45\">",
"     45",
"    </a>",
"    ]. As a result, it should be used briefly for flushing channels prior to drying in preparation for storage. Only isopropyl alcohol (not other forms of alcohol) is acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Rinsing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following high-level disinfection, the scope must be rinsed with water of high microbiological purity (clean water) followed by forced air drying [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/36,47\">",
"     36,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Drying",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final step is a rinse with 70 to 80 percent isopropyl alcohol followed by a second air drying [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ]. The scope should then be dried with a soft, clean lint-free towel [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Storage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoscope should be hung with the tip hanging freely in a well-ventilated, dust free cabinet [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/36,47\">",
"     36,47",
"    </a>",
"    ]. Reprocessing before use does not appear to be necessary after five days of storage provided that reprocessing guidelines have been strictly observed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/48\">",
"     48",
"    </a>",
"    ]. The length of time endoscopes may be stored prior to use without reprocessing is not clear. Reuse of endoscopes within 10 to 14 days appears to be safe, though some societies recommend that scopes be used within 5 to 7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     VARIATION IN RECOMMENDATIONS FROM INTERNATIONAL ORGANIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The British and Australian Societies recommend complete disinfection of endoscopes prior to beginning each day's endoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. This is not recommended by the United States or French Societies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/37,38,50\">",
"     37,38,50",
"    </a>",
"    ]. Most organizations outside the United States recommend that endoscopes be fully immersed in 2 percent glutaraldehyde for 10 minutes between cases while the American and French endoscopic societies recommend 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/37,38,50\">",
"     37,38,50",
"    </a>",
"    ] and the British recommend 20 minutes at the end of the day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/47\">",
"     47",
"    </a>",
"    ]. A consensus statement derived at the World Congress of Gastroenterology in 1998 recommended immersion for at least 10 minutes between cases and 20 minutes at the end of the day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ACCESSORIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most accessories used in the gastrointestinal tract meet the definition of critical devices [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/33\">",
"     33",
"    </a>",
"    ] and should be sterilized. There is ongoing debate about whether \"single use\" accessories should be reused. The French do not permit reuse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/50\">",
"     50",
"    </a>",
"    ]; the United Kingdom guidelines suggest reuse is acceptable if the \"consequences have been considered and the hospital has a documented and validated procedure for doing so\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/47,52\">",
"     47,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in the United States and other countries have documented safe reuse of biopsy forceps, papillotomes, and argon plasma coagulator probes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. There are third party companies that will reprocess such equipment for a cost and will provide the insurance to cover possible liability for problems caused by reprocessed equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/55\">",
"     55",
"    </a>",
"    ]. The FDA considers anyone that reprocesses a device to be a manufacturer, requiring them to obtain 510(k) approval for every",
"    <span class=\"nowrap\">",
"     device/model/mfr",
"    </span>",
"    they plan to reprocess. There may be only three or four major third party reprocessors who have undergone the expense and effort to obtain the necessary FDA approval. Anyone else doing this is in violation of federal law.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutaraldehyde has been implicated in causing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/56\">",
"     56",
"    </a>",
"    ], contact dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/57\">",
"     57",
"    </a>",
"    ], and epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/58\">",
"     58",
"    </a>",
"    ] in those exposed to its fumes or liquid. It has also been suspected as a cause of a chemical colitis mimicking ischemic colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/59\">",
"     59",
"    </a>",
"    ], presenting with cramps, tenesmus, abdominal pain, and rectal bleeding within 48 hours of an endoscopic exam of the colon. Radiographs may demonstrate thumb printing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/60\">",
"     60",
"    </a>",
"    ]. These cases were presumably caused by an inadequately rinsed endoscope. Glutaraldehyde has been removed from use in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     Hydrogen peroxide",
"    </a>",
"    has also been implicated as a cause of intestinal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/61\">",
"     61",
"    </a>",
"    ]. A study described the \"snow white\" sign that appears as a response to contact of the intestinal mucosa with hydrogen peroxide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6312/abstract/61\">",
"     61",
"    </a>",
"    ]. There was no morbidity or mortality noted.",
"   </p>",
"   <p>",
"    A good quality control program should be a part of every endoscopy clinic including frequent bacteriology surveillance of the endoscopes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71945020\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although endoscopic equipment has been implicated in transmitting infection, it appears as if virtually all transmissions have been due to errors in the process of cleaning and disinfecting the equipment or in the breakdown of general infection control practices. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections that have been linked to endoscopy include hepatitis B, hepatitis C, and some bacterial infections. There have been no reported cases of HIV or prion-related disease transmission. (See",
"      <a class=\"local\" href=\"#H71945044\">",
"       'Risk of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal endoscopes meet the definition of semicritical devices (devices that contact the mucous membranes) and require high-level disinfection designed to destroy all microorganisms except some bacterial spores. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Endoscope reprocessing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscope reprocessing can be divided into six separate stages: precleaning, leak testing, cleaning, high-level disinfection, rinsing, and drying. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Endoscope reprocessing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/1\">",
"      Bond WW. Overview of infection control problems: principles in gastrointestinal endoscopy. Gastrointest Endosc Clin N Am 2000; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/2\">",
"      Kimmey MB, Burnett DA, Carr-Locke DA, et al. Technology assessment position paper; Transmission of infection by gastrointestinal endoscopy. Gastrointest Endosc 1993; 39:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/3\">",
"      Nelson DB. Infectious disease complications of GI endoscopy: part II, exogenous infections. Gastrointest Endosc 2003; 57:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/4\">",
"      Birnie GG, Quigley EM, Clements GB, et al. Endoscopic transmission of hepatitis B virus. Gut 1983; 24:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/5\">",
"      McDonald GB, Silverstein FE. Can gastrointestinal endoscopy transmit hepatitis B to patients? Gastrointest Endosc 1976; 22:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/6\">",
"      Morris IM, Cattle DS, Smits BJ. Letter: Endoscopy and transmission of hepatitis B. Lancet 1975; 2:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/7\">",
"      Moncada RE, Denes AE, Berquist KR, et al. Inadvertent exposure of endoscopy patients to viral hepatitis B. Gastrointest Endosc 1978; 24:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/8\">",
"      Bronowicki JP, Venard V, Bott&eacute; C, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 1997; 337:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/9\">",
"      Kozarek RA. Transmission of hepatitis C virus during colonoscopy. N Engl J Med 1997; 337:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/10\">",
"      Tennenbaum R, Colardelle P, Chochon M, et al. [Hepatitis C after retrograde cholangiography]. Gastroenterol Clin Biol 1993; 17:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/11\">",
"      Andrieu J, Barny S, Colardelle P, et al. [Prevalence and risk factors of hepatitis C virus infection in a hospitalized population in a gastroenterology unit. Role of endoscopic biopsies]. Gastroenterol Clin Biol 1995; 19:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/12\">",
"      Chanzy B, Duc-Bin DL, Rousset B, et al. Effectiveness of a manual disinfection procedure in eliminating hepatitis C virus from experimentally contaminated endoscopes. Gastrointest Endosc 1999; 50:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/13\">",
"      Rey JF, Halfon P, Feryn JM, et al. [Risk of transmission of hepatitis C virus by digestive endoscopy]. Gastroenterol Clin Biol 1995; 19:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/14\">",
"      Mikhail NN, Lewis DL, Omar N, et al. Prospective study of cross-infection from upper-GI endoscopy in a hepatitis C-prevalent population. Gastrointest Endosc 2007; 65:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/15\">",
"      Schembre DB. Infectious complications associated with gastrointestinal endoscopy. Gastrointest Endosc Clin N Am 2000; 10:215.",
"     </a>",
"    </li>",
"    <li>",
"     AIDS Alert Dec 1986. p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/17\">",
"      Hanson PJ, Gor D, Clarke JR, et al. Contamination of endoscopes used in AIDS patients. Lancet 1989; 2:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/18\">",
"      Hanson PJ, Gor D, Jeffries DJ, Collins JV. Elimination of high titre HIV from fibreoptic endoscopes. Gut 1990; 31:657.",
"     </a>",
"    </li>",
"    <li>",
"     Bond WW, Ott BJ, Franke KA, et al. Effective use of liquid chemical germicides on medical devices: Instrument design problems. In: Disinfection, sterilization and preservation, 4th Ed, Black SS (Ed), Lea and Febiger, Philadelphia 1991. p.1097.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/20\">",
"      Wallace CG, Agee PM, Demicco DD. Liquid chemical sterilization using peracetic acid. An alternative approach to endoscope processing. ASAIO J 1995; 41:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/21\">",
"      Kovacs BJ, Chen YK, Kettering JD, et al. High-level disinfection of gastrointestinal endoscopes: are current guidelines adequate? Am J Gastroenterol 1999; 94:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/22\">",
"      Foliente RL, Kovacs BJ, Aprecio RM, et al. Efficacy of high-level disinfectants for reprocessing GI endoscopes in simulated-use testing. Gastrointest Endosc 2001; 53:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/23\">",
"      Collins FM. Bactericidal activity of alkaline glutaraldehyde solution against a number of atypical mycobacterial species. J Appl Bacteriol 1986; 61:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/24\">",
"      Akamatsu T, Tabata K, Hironga M, et al. Transmission of Helicobacter pylori infection via flexible fiberoptic endoscopy. Am J Infect Control 1996; 24:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/25\">",
"      Rohr MR, Castro R, Morais M, et al. Risk of Helicobacter pylori transmission by upper gastrointestinal endoscopy. Am J Infect Control 1998; 26:12.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization infection control guidelines for transmissible spongiform encephalopathies: Report of a WHO conference, Geneva, Switzerland, 23-26 March 1999. file://www.who.int/csr/resources/publications/bse/WHO_CDS_CSR_APH_2000_3/en/ (Accessed on April 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/27\">",
"      Rutala WA, Weber DJ. Creutzfeldt-Jakob disease: recommendations for disinfection and sterilization. Clin Infect Dis 2001; 32:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/28\">",
"      Ponchon T. Transmission of hepatitis C and prion diseases through digestive endoscopy: evaluation of risk and recommended practices. Endoscopy 1997; 29:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/29\">",
"      Shmakov AN, Ghosh S. Prion proteins and the gut: une liaison dangereuse? Gut 2001; 48:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/30\">",
"      van Asten JA, Geertsma RE, Dorpema JW. Prions and hospital infections. Lancet 1996; 347:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/31\">",
"      Darbord JC. Inactivation of prions in daily medical practice. Biomed Pharmacother 1999; 53:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/32\">",
"      Manuelidis L. Decontamination of Creutzfeldt-Jakob disease and other transmissible agents. J Neurovirol 1997; 3:62.",
"     </a>",
"    </li>",
"    <li>",
"     Spaulding EH. Chemical disinfection of medical and surgical materials. In: Disinfection, Sterilization, and Preservation, Lawrence CA, Block SS (Eds), Lea and Febiger, Philadelphia 1968. p.517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/34\">",
"      ASGE Quality Assurance In Endoscopy Committee, Petersen BT, Chennat J, et al. Multisociety guideline on reprocessing flexible gastrointestinal endoscopes: 2011. Gastrointest Endosc 2011; 73:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/35\">",
"      Reprocessing of flexible gastrointestinal endoscopes. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1996; 43:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/36\">",
"      Urayama S, Kozarek RA, Sumida S, et al. Mycobacteria and glutaraldehyde: is high-level disinfection of endoscopes possible? Gastrointest Endosc 1996; 43:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/37\">",
"      Infection control during gastrointestinal endoscopy: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1999; 49:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/38\">",
"      Standards of infection control in reprocessing of flexible gastrointestinal endoscopes. Gastroenterol Nurs 2000; 23:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/39\">",
"      Nelson DB, Barkun AN, Block KP, et al. Technology status evaluation report. Transmission of infection by gastrointestinal endoscopy. May 2001. Gastrointest Endosc 2001; 54:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/40\">",
"      American Society for Gastrointestinal Endoscopy, Petersen BT, Adler DG, et al. Automated endoscope reprocessors. Gastrointest Endosc 2009; 69:771.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm192685.htm (Accessed on December 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/42\">",
"      Rutala WA, Weber DJ. Disinfection of endoscopes: review of new chemical sterilants used for high-level disinfection. Infect Control Hosp Epidemiol 1999; 20:69.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.sgna.org/Resources/hldguidelinefinal2007v3.pdf (Accessed on April 01, 2008).",
"    </li>",
"    <li>",
"     www.fda.gov/cdrh/ode/germlab.html (Accessed on April 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/45\">",
"      Rutala WA, Weber DJ. New disinfection and sterilization methods. Emerg Infect Dis 2001; 7:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/46\">",
"      Fraise AP. Choosing disinfectants. J Hosp Infect 1999; 43:255.",
"     </a>",
"    </li>",
"    <li>",
"     www.bsg.org.uk/pdf_word_docs/disinfection.doc (Accessed on April 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/48\">",
"      Rejchrt S, Cerm&aacute;k P, Pavlatov&aacute; L, et al. Bacteriologic testing of endoscopes after high-level disinfection. Gastrointest Endosc 2004; 60:76.",
"     </a>",
"    </li>",
"    <li>",
"     Infection control in endoscopy (Gastroenterology Society of Australia) www.gesa.org.au/ (Accessed on April 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/50\">",
"      Systchenko R, Marchetti B, Canard JN, et al. Guidelines of the French Society of Digestive Endoscopy: recommendations for setting up cleaning and disinfection procedures in gastrointestinal endoscopy. Endoscopy 2000; 32:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/51\">",
"      Tandon RK, Ahuja V. Non-United States guidelines for endoscope reprocessing. Gastrointest Endosc Clin N Am 2000; 10:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/52\">",
"      Ayliffe G, Minimal Access Therapy Decontamination Working Group. Decontamination of minimally invasive surgical endoscopes and accessories. J Hosp Infect 2000; 45:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/53\">",
"      Wilcox CM. Methodology of reprocessing one-time use accessories. Gastrointest Endosc Clin N Am 2000; 10:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/54\">",
"      Jung M, Beilenhoff U, Pietsch M, et al. Standardized reprocessing of reusable colonoscopy biopsy forceps is effective: results of a German multicenter study. Endoscopy 2003; 35:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/55\">",
"      Furman PJ. Third-party reprocessing of endoscopic accessories. Gastrointest Endosc Clin N Am 2000; 10:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/56\">",
"      Corrado OJ, Osman J, Davies RJ. Asthma and rhinitis after exposure to glutaraldehyde in endoscopy units. Hum Toxicol 1986; 5:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/57\">",
"      Nigam PK, Tyagi S, Saxena AK, Misra RS. Dermatitis from zinc pyrithione. Contact Dermatitis 1988; 19:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/58\">",
"      Wiggins P, McCurdy SA, Zeidenberg W. Epistaxis due to glutaraldehyde exposure. J Occup Med 1989; 31:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/59\">",
"      Rozen P, Somjen GJ, Baratz M, et al. Endoscope-induced colitis: description, probable cause by glutaraldehyde, and prevention. Gastrointest Endosc 1994; 40:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/60\">",
"      Birnbaum BA, Gordon RB, Jacobs JE. Glutaraldehyde colitis: radiologic findings. Radiology 1995; 195:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6312/abstract/61\">",
"      Bilotta JJ, Waye JD. Hydrogen peroxide enteritis: the \"snow white\" sign. Gastrointest Endosc 1989; 35:428.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2672 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6312=[""].join("\n");
var outline_f6_10_6312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H71945020\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71945044\">",
"      RISK OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENDOSCOPE REPROCESSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Precleaning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Leak testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cleaning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Automatic washer-disinfector",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      High-level disinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glutaraldehyde",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Peracetic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hydrogen peroxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Peracetic acid/hydrogen peroxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Orthophthaldehyde",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Superoxidized water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chlorine dioxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Quaternary ammonium compounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Isopropyl alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Rinsing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Drying",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Storage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      VARIATION IN RECOMMENDATIONS FROM INTERNATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ACCESSORIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71945020\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_10_6313="Epidemiology of viral gastroenteritis in adults";
var content_f6_10_6313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of viral gastroenteritis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6313/contributors\">",
"     Neil R Blacklow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6313/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/10/6313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/10/6313/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/10/6313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral gastroenteritis is a common illness, affecting populations worldwide. Epidemiologic studies have shown that it is the second most frequent illness encountered by American families [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ]. It affects all age groups at all times of the year, although some individual viruses may target specific age groups during certain seasons.",
"   </p>",
"   <p>",
"    Viral gastroenteritis causes considerable mortality in the developing world; rotavirus alone is estimated to be responsible for more than 500,000 deaths per year, which is approximately one-quarter of all deaths due to infectious diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the United States, viral gastroenteritis causes only a few hundred deaths per year, principally due to rotavirus and norovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. However, morbidity is considerable with approximately 65,000 hospitalizations annually due to rotavirus and a similar number due to norovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/8\">",
"     8",
"    </a>",
"    ]. During Hurricane Katrina, norovirus was responsible for a large outbreak of acute gastroenteritis among evacuees, with substantial secondary spread to medical personnel, police officers, and volunteers who had direct contact with patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific viral agents causing gastroenteritis and their epidemiology will be reviewed here. The clinical manifestations, diagnosis, treatment and prevention of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=see_link\">",
"     \"Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=see_link\">",
"     \"Clinical presentation and diagnosis of rotavirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18868?source=see_link\">",
"     \"Prevention and treatment of viral gastroenteritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of acute infectious gastroenteritis are viral, as indicated by the observation that stool cultures in patients with acute diarrhea have only been positive in 1.5 to 5.6 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef82535 \" href=\"UTD.htm?31/25/32156\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, bacterial causes are responsible for most cases of severe diarrhea in adults: 87 percent in a report of healthy adults in which severe diarrhea was defined as &ge;4 fluid stools per day for more than three days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are four viral agents that are known to be medically important causes of viral gastroenteritis (",
"    <a class=\"graphic graphic_table graphicRef80577 \" href=\"UTD.htm?23/39/24187\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Norovirus",
"     </li>",
"     <li>",
"      Rotavirus",
"     </li>",
"     <li>",
"      Enteric adenovirus",
"     </li>",
"     <li>",
"      Astrovirus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiologic characteristics of each virus differ from those of the others. There are several other putative viral causes of gastroenteritis, such as bocavirus,",
"    <span class=\"nowrap\">",
"     coronavirus/torovirus,",
"    </span>",
"    Aichi virus, picobirnavirus, and pestivirus. However, their medical importance, if any, is not established, and they will not be addressed further. A minority of all suspected cases of viral gastroenteritis lacks an identifiable cause when all available diagnostic modalities are used, and it is assumed that additional etiologic agents remain unidentified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGIC PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral gastroenteritis occurs predominantly in two distinct epidemiologic patterns, endemic and epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ]. These patterns are typified by endemic rotavirus disease in young children and by epidemic norovirus outbreaks in older children and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Endemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endemic form of disease due to group A strains of rotavirus develops mostly in infants and young children (4 to 24 months old). Symptoms are most prominent in this age group and can lead to severe diarrhea and dehydration requiring oral or even parenteral fluid replacement. Rotavirus causes approximately 40 percent of pediatric cases of gastroenteritis requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rotavirus group A is a ubiquitous pathogen in humans; nearly all older children and adults possess serum antibodies to the virus, indicative of prior infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/13\">",
"     13",
"    </a>",
"    ]. Adults can be reinfected with rotavirus, usually asymptomatically, but also may occasionally develop severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/14\">",
"     14",
"    </a>",
"    ]; nosocomial infections can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of rotavirus is being modified by the gradual introduction of rotavirus vaccines in the United States and other developed countries; attempts are underway to deploy these vaccines in developing regions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/2,15\">",
"     2,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endemic pediatric diarrhea is also caused by enteric adenovirus and astrovirus, each of which is responsible for approximately 5 percent of cases worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Sapoviruses are related genetically to noroviruses, and typically infect infants and young children; however, they are less commonly encountered than noroviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/18\">",
"     18",
"    </a>",
"    ], enteric adenoviruses, and astroviruses.",
"   </p>",
"   <p>",
"    Norovirus is the most common viral cause of diarrhea in adults and the second most common viral cause of diarrhea in children (after rotavirus) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemic form of disease typically occurs with norovirus infections, exemplified by the prototype strain, Norwalk virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Family and community-wide outbreaks of acute explosive vomiting and diarrhea, usually lasting 24 to 48 hours, arise among school age children and both child and adult family contacts of these patients. In contrast to endemic rotaviral disease, infants and young children are usually spared.",
"   </p>",
"   <p>",
"    More than 90 percent of viral gastroenteritis outbreaks in the United States are caused by norovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Outbreak settings are varied, ranging from cruise ships to nursing homes to athletic teams to military personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/20-23\">",
"     20-23",
"    </a>",
"    ], and often involve fecally contaminated foods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. Indeed, norovirus is the most common cause of foodborne disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/24\">",
"     24",
"    </a>",
"    ]. Approximately one-half of outbreaks have been associated with high attack rates (&gt;10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic criteria for differentiating outbreaks of gastroenteritis due to norovirus from bacterial pathogens were established in 1982, due to the lack of accessible diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/25\">",
"     25",
"    </a>",
"    ]. The Kaplan criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vomiting in more than half of affected persons",
"     </li>",
"     <li>",
"      Mean (or median) incubation period of 24 to 48 hours",
"     </li>",
"     <li>",
"      Mean (or median) duration of illness of 12 to 60 hours",
"     </li>",
"     <li>",
"      No bacterial pathogen isolated in stool culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simple and sensitive diagnostic assays for large-scale use are still not easily available, so the Kaplan criteria continue to play a role in epidemiologic assessment. These criteria were evaluated in a large data set of &gt;4000 foodborne outbreaks, in which norovirus and bacterial agents were confirmed in 148 and 214 cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/26\">",
"     26",
"    </a>",
"    ]. The Kaplan criteria were found to be highly specific (99 percent) and moderately sensitive (68 percent) in discriminating norovirus from bacterial etiologies.",
"   </p>",
"   <p>",
"    Epidemic viral gastroenteritis is also occasionally caused by astrovirus, rotavirus, and the much less commonly encountered group B and C strains of rotavirus. Group B strains of rotavirus have caused disease outbreaks only in China to date [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blended patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many rotavirus and norovirus infections fit within the distinct epidemiology outlined above, there is some blending of these patterns. Rotavirus infections, for example, occur predominantly in the winter months in temperate climates. Thus, despite their overall endemic characteristics, rotavirus infections in a winter involving many cases may sometimes appear more epidemic-like. It is also now clear that noroviruses commonly cause endemic pediatric and adult diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/8,19,28\">",
"     8,19,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VIRUS-SPECIFIC EPIDEMIOLOGIC CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the epidemiologic characteristics of each of the specific groups of viruses often differ from one another but sometimes may share similar characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rotavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotavirus group A is the leading cause of viral gastroenteritis worldwide due to its predilection for causing dehydrating diarrhea in infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/29\">",
"     29",
"    </a>",
"    ]. Diarrhea due to this virus is particularly severe in malnourished children of the developing world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than half a million infants and young children worldwide die of rotavirus gastroenteritis each year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Data from the United States prior to the 2006 licensure of rotavirus vaccines revealed an estimated 3 million cases per year of rotavirus diarrhea, resulting in 500,000 office visits, about 65,000 hospitalizations, and approximately 30 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/2,4,5,30\">",
"     2,4,5,30",
"    </a>",
"    ]. Prevaccine data from Europe and the United States show that annual hospitalization rates for rotavirus gastroenteritis have been between 1 in 20 and 1 in 80 children under five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/31\">",
"     31",
"    </a>",
"    ]. Preliminary data suggests that numbers of rotavirus diarrhea cases have diminished substantially in the United States since the introduction of vaccines; for example, positive laboratory diagnostic tests have decreased by 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually every nonimmunized child develops rotavirus gastroenteritis by three years of age. Reinfections are common thereafter, but symptoms are typically less severe. It is estimated that more than 300 million dollars have been spent each year on direct medical costs for rotavirus diarrhea in the United States with a total economic impact of one billion dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/32\">",
"     32",
"    </a>",
"    ]. Clearly, rotavirus is a ubiquitous pathogen of humans, with major clinical and economic impacts: this was the rationale for development and licensure of a vaccine in the United States to prevent serious rotavirus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Age groups affected",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although infants and young children are the major targets for serious rotavirus infections, reinfections in older children and adults, while usually asymptomatic, can occasionally be surprisingly severe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1,14,36\">",
"     1,14,36",
"    </a>",
"    ]. Symptomatic nosocomial infections can occur in nurses, medical students, and house officers caring for infected infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ]. Rotavirus can cause travelers' diarrhea in adults but does so uncommonly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .) Group B strains of rotavirus have produced severe epidemics of diarrhea among adults in China, but these epidemics have not spread elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virus is transmitted principally by the fecal-oral route [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ]. The incubation period for infection is less than 48 hours. Fecal shedding is generally thought to last about 10 days, although one Australian report found that one-third of immunocompetent children with severe rotavirus diarrhea shed the virus for at least 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/37\">",
"     37",
"    </a>",
"    ]. Individuals handling diapers of infected children can easily spread the infection if they do not wash their hands carefully, and disease outbreaks are common in daycare centers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the family unit, about 50 percent of exposed children and 15 to 30 percent of exposed adults will become infected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/39\">",
"     39",
"    </a>",
"    ]. A very small inoculum is contagious since the feces of infected children usually contain no more than 100 colony forming units per gram.",
"   </p>",
"   <p>",
"    There is indirect evidence that rotavirus may be transmitted by the respiratory route [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this is clearly not a primary mechanism for spread of the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Seasonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rotavirus infections are endemic worldwide, they do peak during the cooler months of the year in temperate climates (eg, during December to April in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/41\">",
"     41",
"    </a>",
"    ]. However, infections do not show this pattern in the tropics but rather occur year round. It is interesting that in the United States an unexplained yearly wave of rotavirus infections spreads across the country from west to east, starting in the southwest and ending in the northeast [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/41\">",
"     41",
"    </a>",
"    ]. A similar west to east pattern has been noted in Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Norovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Norovirus is the major cause of epidemic viral gastroenteritis. It is also the most common cause of all forms of gastroenteritis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. Disease outbreaks occur worldwide and affect all ages ranging from school children to elderly populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitive tests for the identification of noroviruses have been developed, such as reverse-transcription polymerase chain reaction (RT-PCR) assays, thereby enhancing our understanding of the medical and economic importance of these agents. Current estimates are that noroviruses cause 23 million episodes of illness, 65,000 hospitalizations, and 300 deaths each year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/6,8,20,42\">",
"     6,8,20,42",
"    </a>",
"    ], with most fatalities occurring in elderly patients. Although norovirus typically causes disease epidemics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/6,7,20\">",
"     6,7,20",
"    </a>",
"    ], it is also a common cause of endemic diarrhea in community settings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately 5 to 36 percent of outpatient visits for diarrhea are due to norovirus with similar percentages for patients hospitalized for gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both sapovirus and norovirus are caliciviruses. However, the former is much less common than norovirus, accounting for approximately 2 to 5 percent of pediatric diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/18,43\">",
"     18,43",
"    </a>",
"    ] and some disease outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/44\">",
"     44",
"    </a>",
"    ]. Because sapovirus is not as medically important or common as norovirus, the remainder of this discussion will focus entirely on norovirus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Age groups affected",
"    </span>",
"    &nbsp;&mdash;&nbsp;Norovirus epidemics affect all age groups; antibody seroprevalence rises progressively during childhood so that more than 90 percent of young adults are seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/18,28,45\">",
"     18,28,45",
"    </a>",
"    ]. However, immunity is not long lasting, and reinfections throughout life are believed to be common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/46\">",
"     46",
"    </a>",
"    ]. Exposure over time to a diversity of norovirus strains may also result in repeated infections. Norovirus has a major role in outbreaks of gastroenteritis in elderly persons, typically seen in long-term care facilities (LTCF) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Outbreak settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is through the study of disease outbreaks that much has been learned about the epidemiology of noroviruses. They have been identified by RT-PCR as the cause of 96 percent of 90 outbreaks of nonbacterial gastroenteritis reported to the Centers for Disease Control and Prevention (CDC) from January 1996 to June 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/48\">",
"     48",
"    </a>",
"    ], and of 93 percent of 284 outbreaks of nonbacterial gastroenteritis from July 1997 to June 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/20\">",
"     20",
"    </a>",
"    ]. In the latter study, nearly two-thirds of outbreaks occurred in restaurants, catered meals, nursing homes, and hospitals. The distribution of outbreaks in various venues was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restaurants or events with catered meals (39 percent)",
"     </li>",
"     <li>",
"      LTCF and hospitals (25 percent)",
"     </li>",
"     <li>",
"      Schools, daycare centers, and camps (13 percent)",
"     </li>",
"     <li>",
"      Vacation destinations including cruise ships (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other settings have included prisons, military populations, community locations, and athletic teams [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/49\">",
"     49",
"    </a>",
"    ]. Considerable attention has been given during 2002 and 2003 in the press to numerous norovirus outbreaks occurring on cruise ships and among military personnel serving in Afghanistan [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/6,21,50\">",
"     6,21,50",
"    </a>",
"    ]. During 2004-2005, major norovirus outbreaks occurred among military personnel serving in Iraq [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/22\">",
"     22",
"    </a>",
"    ]. Since 2002 some outbreaks of norovirus infection have been caused by a new variant GII.4 genotype strain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/51\">",
"     51",
"    </a>",
"    ]. The GII.4 genotype has spread globally to become the predominant norovirus strain in circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CDC surveillance studies of foodborne disease show that two-thirds of all food-related illnesses are due to noroviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/24\">",
"     24",
"    </a>",
"    ]. Consumption of a number of different foods poses a risk including: contaminated oysters and clams, water supplies, cold foods (eg, salads, sandwiches, bakery products such as frosting), and fruits (eg, celery, melon, raspberries). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=see_link\">",
"     \"Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Norovirus is commonly spread nosocomially, as the virus can be shed for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Immunocompromised patients are at high risk for serious norovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volunteer studies have clearly established a fecal-oral route of spread for noroviruses, with an incubation period of one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ]. These viruses are highly transmissible, requiring a low infectious dose of only 10 to 100 viral particles, which readily explains their frequent involvement in food-related illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noroviruses are shed in the feces for up to two weeks after experimental infection of volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/57\">",
"     57",
"    </a>",
"    ]. Some patients (26 percent in a community-based study) shed virus for up to three weeks after the onset of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to large outbreaks from consumption of contaminated food and water, noroviruses are efficiently spread person-to-person [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/7,39\">",
"     7,39",
"    </a>",
"    ]. In a well-documented secondary outbreak, 43 members of a football team developed gastrointestinal symptoms from a single food source [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/58\">",
"     58",
"    </a>",
"    ]. Eleven members of the opposing team later developed an acute gastrointestinal illness with an identical strain, even though they had not shared the same food. These secondary cases suggest that additional routes, other than fecal-oral, may be responsible. Viral particles have been found in vomitus, and ingestion of airborne droplets of vomitus-containing viral particles has been postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noroviruses are extremely stable, resisting heating to 60&ordm;C as well as chlorine disinfection suitable for killing most bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/60\">",
"     60",
"    </a>",
"    ]; thus, these viruses persist on environmental surfaces such as computer equipment or fomites, which presents another likely route for transmission outlined in several epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/24,61-63\">",
"     24,61-63",
"    </a>",
"    ]. In hospital settings, symptomatic patients and healthcare workers appear to be involved more often than asymptomatic shedders. In one study asymptomatic healthcare workers rarely contributed to transmission despite high levels of virus shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Seasonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although norovirus is the principal cause of what was previously called \"winter vomiting disease\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ], outbreaks clearly occur in all months, albeit with a small peak during the winter months in temperate climates in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the extensive three-year CDC study of 284 outbreaks did not reveal seasonal differences [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Enteric adenovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric adenovirus (ie, adenovirus serotypes 40 and 41) causes approximately 3 to 15 percent of endemic pediatric gastroenteritis in temperate climates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/17,66,67\">",
"     17,66,67",
"    </a>",
"    ]. Although the epidemiology is not fully understood, this infection is considered to be of considerably less medical importance than infections caused by rotavirus or norovirus. Illness occurs predominantly in children under two years old [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ] and lasts for 5 to 12 days. The incubation period is 8 to 10 days, which is considerably longer than that seen with rotavirus and norovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"     1",
"    </a>",
"    ]. The route of viral transmission is thought to be person-to-person, although this virus is much less contagious than rotavirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/39,68\">",
"     39,68",
"    </a>",
"    ]. Nosocomial infections have been documented (eg, in immunocompromised children), but disease in adults is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/17,69\">",
"     17,69",
"    </a>",
"    ]. No seasonality has been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Astrovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Astrovirus causes a common endemic childhood diarrhea responsible for 3 to 9 percent of cases in studies performed worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/16,70\">",
"     16,70",
"    </a>",
"    ]. It is responsible for 4 to 7 percent of diarrheas in daycare centers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/71\">",
"     71",
"    </a>",
"    ], and is a common cause of nosocomial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/72\">",
"     72",
"    </a>",
"    ]. In one study of hospitalized children under the age of 10 years over a five-year period, astrovirus produced 6.8 percent of cases of community-acquired diarrhea leading to hospitalization and 16.2 percent of episodes of nosocomial diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Astrovirus also causes illness in immunocompromised persons and elderly institutionalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. One report revealed astrovirus to cause 12 percent of acute diarrhea cases in patients with the acquired immunodeficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/74\">",
"     74",
"    </a>",
"    ]; in that study it was the most common identifiable pathogen, viral, bacterial, or parasitic. Another study identified astrovirus in 4 percent of episodes of diarrhea occurring after bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike norovirus, astrovirus is an uncommon cause of epidemic gastroenteritis, although a few outbreaks have been described. Disease outbreaks have occurred in LTCF and on geriatric wards.",
"   </p>",
"   <p>",
"    Serum antibody prevalence levels rise rapidly to astroviruses during early childhood, and most adults possess antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/77\">",
"     77",
"    </a>",
"    ]. Infection is spread primarily person to person by the fecal-oral route and also via contaminated food and water [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/78\">",
"     78",
"    </a>",
"    ]. There is a winter peak of infections in temperate regions and a rainy season predominance in tropical areas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/10/6313/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=see_link\">",
"       \"Patient information: Viral gastroenteritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124178341\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral gastroenteritis is a common illness, affecting populations worldwide. Epidemiologic studies have shown that it is the second most frequent illness encountered by American families. It affects all age groups at all times of the year, although some individual viruses may target specific age groups during certain seasons. Viral gastroenteritis causes considerable mortality in the developing world; rotavirus alone is estimated to be responsible for more than 500,000 deaths per year, which is approximately one-quarter of all deaths due to infectious diarrhea. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of acute infectious gastroenteritis are viral. There are four viral agents that are known to be medically important causes of viral gastroenteritis (",
"      <a class=\"graphic graphic_table graphicRef80577 \" href=\"UTD.htm?23/39/24187\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Norovirus",
"     </li>",
"     <li>",
"      Rotavirus",
"     </li>",
"     <li>",
"      Enteric adenovirus",
"     </li>",
"     <li>",
"      Astrovirus (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiologic agents'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral gastroenteritis occurs predominantly in two distinct epidemiologic patterns, endemic and epidemic. These patterns are typified by endemic rotavirus disease in young children and by epidemic norovirus outbreaks in older children and adults. More than 90 percent of viral gastroenteritis outbreaks in the United States are caused by norovirus. Outbreak settings are varied, ranging from cruise ships to nursing homes to athletic teams to military personnel, and often involve fecally contaminated foods. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiologic patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rotavirus group A is the leading cause of viral gastroenteritis worldwide due to its predilection for causing dehydrating diarrhea in infants and young children. Diarrhea due to this virus is particularly severe in malnourished children of the developing world. The virus is transmitted principally by the fecal-oral route. The incubation period for infection is less than 48 hours. Although rotavirus infections are endemic worldwide, they peak during the cooler months of the year in temperate climates (eg, during December to April in the United States). However, infections do not show this pattern in the tropics but rather occur year round. &nbsp;(See",
"      <a class=\"local\" href=\"#H8\">",
"       'Rotavirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Norovirus is the major cause of epidemic viral gastroenteritis. It is also the most common cause of all forms of gastroenteritis in adults. Disease outbreaks occur worldwide and affect all ages, ranging from school children to elderly populations. Although norovirus typically causes disease epidemics, it is also a common cause of endemic diarrhea in community settings. Transmission occurs via the fecal-oral route, with an incubation period of one to two days. These viruses are highly transmissible, requiring a low infectious dose of only 10 to 100 viral particles. Although norovirus is the principal cause of what was previously called \"winter vomiting disease,\" outbreaks clearly occur in all months. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Norovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteric adenovirus (ie, adenovirus serotypes 40 and 41) causes approximately 3 to 15 percent of endemic pediatric gastroenteritis in temperate climates. Although the epidemiology is not fully understood, this infection is considered to be of considerably less medical importance than infections caused by rotavirus or norovirus. Illness occurs predominantly in children under two years old. The incubation period is 8 to 10 days. The route of viral transmission is thought to be person-to-person, although this virus is much less contagious than rotavirus. Nosocomial infections have been documented (eg, in immunocompromised children), but disease in adults is uncommon. No seasonality has been described. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Enteric adenovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Astrovirus causes a common endemic childhood diarrhea responsible for 3 to 9 percent of cases in studies performed worldwide. It is responsible for 4 to 7 percent of diarrheas in daycare centers, and is a common cause of nosocomial disease. Astrovirus also causes illness in immunocompromised persons (eg, AIDS, bone marrow transplantation) and elderly institutionalized patients. Unlike norovirus, astrovirus is an uncommon cause of epidemic gastroenteritis. Infection is spread primarily person to person by the fecal-oral route and also via contaminated food and water. There is a winter peak of infections in temperate regions and a rainy season predominance in tropical areas. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Astrovirus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/1\">",
"      Blacklow NR, Greenberg HB. Viral gastroenteritis. N Engl J Med 1991; 325:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/2\">",
"      Parashar UD, Glass RI. Rotavirus vaccines--early success, remaining questions. N Engl J Med 2009; 360:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/3\">",
"      Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/4\">",
"      Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/5\">",
"      Parashar UD, Holman RC, Clarke MJ, et al. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis 1998; 177:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of acute gastroenteritis associated with Norwalk-like viruses among British military personnel--Afghanistan, May 2002. MMWR Morb Mortal Wkly Rep 2002; 51:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Norovirus activity--United States, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/8\">",
"      Patel MM, Widdowson MA, Glass RI, et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008; 14:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Norovirus outbreak among evacuees from hurricane Katrina--Houston, Texas, September 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/10\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/11\">",
"      Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996; 22:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/12\">",
"      Glass RI, Bresee JS, Parashar UD, et al. First rotavirus vaccine licensed: is there really a need? Acta Paediatr Suppl 1999; 88:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/13\">",
"      Kapikian AZ, Kim HW, Wyatt RG, et al. Human reovirus-like agent as the major pathogen associated with \"winter\" gastroenteritis in hospitalized infants and young children. N Engl J Med 1976; 294:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/14\">",
"      Echeverria P, Blacklow NR, Cukor GG, et al. Rotavirus as a cause of severe gastroenteritis in adults. J Clin Microbiol 1983; 18:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/15\">",
"      Danchin MH, Bines JE. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med 2009; 361:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/16\">",
"      Pang XL, Vesikari T. Human astrovirus-associated gastroenteritis in children under 2 years of age followed prospectively during a rotavirus vaccine trial. Acta Paediatr 1999; 88:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/17\">",
"      Kotloff KL, Losonsky GA, Morris JG Jr, et al. Enteric adenovirus infection and childhood diarrhea: an epidemiologic study in three clinical settings. Pediatrics 1989; 84:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/18\">",
"      Rockx B, De Wit M, Vennema H, et al. Natural history of human calicivirus infection: a prospective cohort study. Clin Infect Dis 2002; 35:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/19\">",
"      Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/20\">",
"      Fankhauser RL, Monroe SS, Noel JS, et al. Epidemiologic and molecular trends of \"Norwalk-like viruses\" associated with outbreaks of gastroenteritis in the United States. J Infect Dis 2002; 186:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/21\">",
"      Widdowson MA, Cramer EH, Hadley L, et al. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus--United States, 2002. J Infect Dis 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/22\">",
"      Thornton SA, Sherman SS, Farkas T, et al. Gastroenteritis in US Marines during Operation Iraqi Freedom. Clin Infect Dis 2005; 40:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/23\">",
"      Matson DO. Norovirus gastroenteritis in US Marines in Iraq. Clin Infect Dis 2005; 40:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/24\">",
"      Bresee JS, Widdowson MA, Monroe SS, Glass RI. Foodborne viral gastroenteritis: challenges and opportunities. Clin Infect Dis 2002; 35:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/25\">",
"      Kaplan JE, Gary GW, Baron RC, et al. Epidemiology of Norwalk gastroenteritis and the role of Norwalk virus in outbreaks of acute nonbacterial gastroenteritis. Ann Intern Med 1982; 96:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/26\">",
"      Turcios RM, Widdowson MA, Sulka AC, et al. Reevaluation of epidemiological criteria for identifying outbreaks of acute gastroenteritis due to norovirus: United States, 1998-2000. Clin Infect Dis 2006; 42:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/27\">",
"      Hung T, Chen GM, Wang CG, et al. Waterborne outbreak of rotavirus diarrhoea in adults in China caused by a novel rotavirus. Lancet 1984; 1:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/28\">",
"      de Wit MA, Koopmans MP, Kortbeek LM, et al. Etiology of gastroenteritis in sentinel general practices in the netherlands. Clin Infect Dis 2001; 33:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/29\">",
"      Grimwood K, Buttery JP. Clinical update: rotavirus gastroenteritis and its prevention. Lancet 2007; 370:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/30\">",
"      Bernstein DI, Sack DA, Reisinger K, et al. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002; 186:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/31\">",
"      Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J Infect 2002; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/32\">",
"      Prevention of rotavirus gastroenteritis among infants and children. MMWR Morb Mortal Wkly Rep 2009; 58(RR-2):.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/33\">",
"      Ruiz-Palacios GM, P&eacute;rez-Schael I, Vel&aacute;zquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/34\">",
"      Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/35\">",
"      Heaton PM, Ciarlet M. Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 2007; 45:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/36\">",
"      Vel&aacute;zquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/37\">",
"      Richardson S, Grimwood K, Gorrell R, et al. Extended excretion of rotavirus after severe diarrhoea in young children. Lancet 1998; 351:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/38\">",
"      Bartlett AV 3rd, Reves RR, Pickering LK. Rotavirus in infant-toddler day care centers: epidemiology relevant to disease control strategies. J Pediatr 1988; 113:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/39\">",
"      Musher DM, Musher BL. Contagious acute gastrointestinal infections. N Engl J Med 2004; 351:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/40\">",
"      Koopman JS, Monto AS. The Tecumseh Study. XV: Rotavirus infection and pathogenicity. Am J Epidemiol 1989; 130:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/41\">",
"      LeBaron CW, Lew J, Glass RI, et al. Annual rotavirus epidemic patterns in North America. Results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. Rotavirus Study Group. JAMA 1990; 264:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/42\">",
"      Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/43\">",
"      Nakata S, Honma S, Numata KK, et al. Members of the family caliciviridae (Norwalk virus and Sapporo virus) are the most prevalent cause of gastroenteritis outbreaks among infants in Japan. J Infect Dis 2000; 181:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/44\">",
"      Pang XL, Lee BE, Tyrrell GJ, Preiksaitis JK. Epidemiology and genotype analysis of sapovirus associated with gastroenteritis outbreaks in Alberta, Canada: 2004-2007. J Infect Dis 2009; 199:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/45\">",
"      Parker SP, Cubitt WD, Jiang X. Enzyme immunoassay using baculovirus-expressed human calicivirus (Mexico) for the measurement of IgG responses and determining its seroprevalence in London, UK. J Med Virol 1995; 46:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/46\">",
"      Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 1990; 161:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/47\">",
"      Green KY, Belliot G, Taylor JL, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. J Infect Dis 2002; 185:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/48\">",
"      Fankhauser RL, Noel JS, Monroe SS, et al. Molecular epidemiology of \"Norwalk-like viruses\" in outbreaks of gastroenteritis in the United States. J Infect Dis 1998; 178:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of norovirus gastroenteritis among attendees at a family reunion--Grant County, West Virginia, October 2006. MMWR Morb Mortal Wkly Rep 2007; 56:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of gastroenteritis associated with noroviruses on cruise ships--United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/51\">",
"      Lopman B, Vennema H, Kohli E, et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet 2004; 363:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/52\">",
"      Tu ET, Bull RA, Greening GE, et al. Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. Clin Infect Dis 2008; 46:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/53\">",
"      Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis 2009; 200:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/54\">",
"      Koo HL, DuPont HL. Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis 2009; 49:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/55\">",
"      Siebenga JJ, Beersma MF, Vennema H, et al. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. J Infect Dis 2008; 198:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/56\">",
"      Koo HL, Ajami NJ, Jiang ZD, et al. A nosocomial outbreak of norovirus infection masquerading as clostridium difficile infection. Clin Infect Dis 2009; 48:e75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/57\">",
"      Okhuysen PC, Jiang X, Ye L, et al. Viral shedding and fecal IgA response after Norwalk virus infection. J Infect Dis 1995; 171:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/58\">",
"      Becker KM, Moe CL, Southwick KL, MacCormack JN. Transmission of Norwalk virus during football game. N Engl J Med 2000; 343:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/59\">",
"      Marks PJ, Vipond IB, Carlisle D, et al. Evidence for airborne transmission of Norwalk-like virus (NLV) in a hotel restaurant. Epidemiol Infect 2000; 124:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/60\">",
"      Keswick BH, Satterwhite TK, Johnson PC, et al. Inactivation of Norwalk virus in drinking water by chlorine. Appl Environ Microbiol 1985; 50:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/61\">",
"      Evans MR, Meldrum R, Lane W, et al. An outbreak of viral gastroenteritis following environmental contamination at a concert hall. Epidemiol Infect 2002; 129:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/62\">",
"      Kuusi M, Nuorti JP, Maunula L, et al. A prolonged outbreak of Norwalk-like calicivirus (NLV) gastroenteritis in a rehabilitation centre due to environmental contamination. Epidemiol Infect 2002; 129:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/63\">",
"      Centers for Disease Control and Prevention (CDC). Norovirus outbreak in an elementary school--District of Columbia, February 2007. MMWR Morb Mortal Wkly Rep 2008; 56:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/64\">",
"      Sukhrie FH, Teunis P, Vennema H, et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis 2012; 54:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/65\">",
"      Mounts AW, Ando T, Koopmans M, et al. Cold weather seasonality of gastroenteritis associated with Norwalk-like viruses. J Infect Dis 2000; 181 Suppl 2:S284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/66\">",
"      Uhnoo I, Wadell G, Svensson L, Johansson ME. Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children. J Clin Microbiol 1984; 20:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/67\">",
"      Cunliffe NA, Booth JA, Elliot C, et al. Healthcare-associated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. Emerg Infect Dis 2010; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/68\">",
"      Lew JF, LeBaron CW, Glass RI, et al. Recommendations for collection of laboratory specimens associated with outbreaks of gastroenteritis. MMWR Recomm Rep 1990; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/69\">",
"      Rodriguez WJ, Kim HW, Brandt CD, et al. Fecal adenoviruses from a longitudinal study of families in metropolitan Washington, D.C.: laboratory, clinical, and epidemiologic observations. J Pediatr 1985; 107:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/70\">",
"      Herrmann JE, Taylor DN, Echeverria P, Blacklow NR. Astroviruses as a cause of gastroenteritis in children. N Engl J Med 1991; 324:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/71\">",
"      Mitchell DK, Matson DO, Jiang X, et al. Molecular epidemiology of childhood astrovirus infection in child care centers. J Infect Dis 1999; 180:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/72\">",
"      Esahli H, Breb&auml;ck K, Bennet R, et al. Astroviruses as a cause of nosocomial outbreaks of infant diarrhea. Pediatr Infect Dis J 1991; 10:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/73\">",
"      Dennehy PH, Nelson SM, Spangenberger S, et al. A prospective case-control study of the role of astrovirus in acute diarrhea among hospitalized young children. J Infect Dis 2001; 184:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/74\">",
"      Grohmann GS, Glass RI, Pereira HG, et al. Enteric viruses and diarrhea in HIV-infected patients. Enteric Opportunistic Infections Working Group. N Engl J Med 1993; 329:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/75\">",
"      Midthun K, Greenberg HB, Kurtz JB, et al. Characterization and seroepidemiology of a type 5 astrovirus associated with an outbreak of gastroenteritis in Marin County, California. J Clin Microbiol 1993; 31:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/76\">",
"      Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/77\">",
"      Kurtz J, Lee T. Astrovirus gastroenteritis age distribution of antibody. Med Microbiol Immunol 1978; 166:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/78\">",
"      Appleton H. Small round viruses: classification and role in food-borne infections. Ciba Found Symp 1987; 128:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/79\">",
"      Bates PR, Bailey AS, Wood DJ, et al. Comparative epidemiology of rotavirus, subgenus F (types 40 and 41) adenovirus and astrovirus gastroenteritis in children. J Med Virol 1993; 39:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/10/6313/abstract/80\">",
"      Cruz JR, Bartlett AV, Herrmann JE, et al. Astrovirus-associated diarrhea among Guatemalan ambulatory rural children. J Clin Microbiol 1992; 30:1140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2684 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6313=[""].join("\n");
var outline_f6_10_6313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1124178341\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGIC PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Endemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blended patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VIRUS-SPECIFIC EPIDEMIOLOGIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rotavirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Age groups affected",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Seasonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Norovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Age groups affected",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Outbreak settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Seasonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Enteric adenovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Astrovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1124178341\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2684|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/25/32156\" title=\"table 1\">",
"      Stool culture isolates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24187\" title=\"table 2\">",
"      Major gastroenteritis viruses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=related_link\">",
"      Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18868?source=related_link\">",
"      Prevention and treatment of viral gastroenteritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_10_6314="ALCL sinusoidal infiltration";
var content_f6_10_6314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anaplastic large cell lymphoma sinusoidal infiltration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Case of common pattern demonstrates a sinusoidal infiltration pattern. Hematoxylin and eosin, 20x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6314=[""].join("\n");
var outline_f6_10_6314=null;
var title_f6_10_6315="Patch test relevance";
var content_f6_10_6315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical relevance of patch test reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Definite",
"       </td>",
"       <td>",
"        Allergen found in patient's environment, dermatitis corresponds to point of contact with allergen, and dermatitis improved upon isolation of the allergen or recurred with rechallenge (provocative use test).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable",
"       </td>",
"       <td>",
"        Same criteria as above but no ability to obtain follow-up information on improvement status or rechallenge.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible",
"       </td>",
"       <td>",
"        One criteria needs to be met from \"definite\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not traced",
"       </td>",
"       <td>",
"        No evidence of current or past exposure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Past",
"       </td>",
"       <td>",
"        Allergen found in past environment.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6315=[""].join("\n");
var outline_f6_10_6315=null;
var title_f6_10_6316="A1C and blood sugar PI";
var content_f6_10_6316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A1C level and average blood sugar",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        If your A1C level is (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        That means your average blood sugar level during the past 2 to 3 months was",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        If you live",
"        <em>",
"         within the US",
"        </em>",
"        , use these values. Your blood sugar is measured in milligrams/deciliter (mg/dL).",
"       </td>",
"       <td class=\"subtitle2\">",
"        If you live",
"        <em>",
"         outside the US",
"        </em>",
"        , use these values. Your blood sugar is measured in millimoles/liter (mmol/L).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        269",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        298",
"       </td>",
"       <td>",
"        16.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        326",
"       </td>",
"       <td>",
"        18.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        355",
"       </td>",
"       <td>",
"        19.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The A1C blood test tells you what your average blood sugar level has been for the past 2 to 3 months. This table lists which A1C levels go with which average blood sugar levels. Blood sugar is measured differently within the United States than it is in most other countries. The column in the middle is for people in the United States. The column on the right is for people who live outside the United States.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6316=[""].join("\n");
var outline_f6_10_6316=null;
var title_f6_10_6317="Differential Kawasaki disease";
var content_f6_10_6317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of Kawasaki disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kawasaki disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxic shock syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Streptococcal scarlet fever",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stevens-Johnson syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic onset JIA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Age (years)",
"        </strong>",
"       </td>",
"       <td>",
"        Usually &lt;5",
"       </td>",
"       <td>",
"        Usually &gt;10",
"       </td>",
"       <td>",
"        Usually 2 to 8",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        2 to 5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Fever",
"        </strong>",
"       </td>",
"       <td>",
"        Persistent",
"       </td>",
"       <td>",
"        Usually &lt;10 days",
"       </td>",
"       <td>",
"        Variable, usually &lt;10 days",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Eyes",
"        </strong>",
"       </td>",
"       <td>",
"        Nonexudative conjunctivitis, limbal sparing, anterior uveitis",
"       </td>",
"       <td>",
"        Conjunctivitis",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Exudative conjunctivitis, keratitis",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Oral mucosa",
"        </strong>",
"       </td>",
"       <td>",
"        Diffuse erythema, \"strawberry tongue\"",
"       </td>",
"       <td>",
"        Erythematous",
"       </td>",
"       <td>",
"        Pharyngitis, \"strawberry tongue\"",
"       </td>",
"       <td>",
"        Erythema, ulceration, pseudomembrane formation",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Peripheral extremities",
"        </strong>",
"       </td>",
"       <td>",
"        Erythema of palms and soles, indurative edema, periungual desquamation",
"       </td>",
"       <td>",
"        Swelling of hands and feet",
"       </td>",
"       <td>",
"        Flaky desquamation",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Arthritis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Rash",
"        </strong>",
"       </td>",
"       <td>",
"        Erythematous polymorphous; targetoid or purpuric in 20 percent",
"       </td>",
"       <td>",
"        Erythroderma",
"       </td>",
"       <td>",
"        Papular erythroderma Pastia's lines, circumoral palor",
"       </td>",
"       <td>",
"        Target lesions",
"       </td>",
"       <td>",
"        Transient, salmon, pink",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Cervical lymph nodes",
"        </strong>",
"       </td>",
"       <td>",
"        Nonpurulent swelling",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Painful swelling",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Diffuse adenopathy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Other",
"        </strong>",
"       </td>",
"       <td>",
"        Arthritis",
"       </td>",
"       <td>",
"        Mental status changes, coagulopathy, shock",
"       </td>",
"       <td>",
"        Throat culture positive for group A streptococcus",
"       </td>",
"       <td>",
"        Arthralgia, associated herpesvirus infection (30-75 percent)",
"       </td>",
"       <td>",
"        Arthritis, pericarditis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Characteristic lab results",
"        </strong>",
"       </td>",
"       <td>",
"        Systemic inflammation, anemia, transaminitis",
"       </td>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        Positive throat culture",
"       </td>",
"       <td>",
"        Associated herpesvirus infection 30 to 50 percent",
"       </td>",
"       <td>",
"        Systemic inflammation, anemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     JIA: juvenile idiopathic arthritis.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Yanagihara R, Todd JK, Am J Dis Childhood 1980; 134:603.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6317=[""].join("\n");
var outline_f6_10_6317=null;
var title_f6_10_6318="Fasciculations deltoid and triceps ALS";
var content_f6_10_6318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/66062/alsarfsc_conv.mp4?title=Fasciculations+deltoid+and+triceps+ALS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fasciculations of right deltoid and triceps in amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lower motor neuron sign, fasciculations are apparent in the right deltoid (white arrow), biceps and triceps muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nestor Galvez-Jimenez, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6318=[""].join("\n");
var outline_f6_10_6318=null;
var title_f6_10_6319="Gram stain wound 1";
var content_f6_10_6319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain wound 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_10_6319=[""].join("\n");
var outline_f6_10_6319=null;
